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web address http://www.blackwellpublishing.com/products/ journals/suppmat/ 
ejb/ejbtab4.htm. Such abbreviations are used in the text and the legends of figures 
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AAV   Adeno-associated virus 
aa   Amino acid 
BLAST  Basic Local Alignment Search Tool 
CIAP   Calf intestine alkaline phosphatase 
ChikV   Chikungunya virus 
CMV   Cytomegalovirus 
CPE   Cytopathic effect 
ddH2O  doubly deionized water 
DPT   Days post transfection 
DPS   Days post splitting 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO  Dimethyl sulfoxide 
dNTP   deoxyribonucleoside triphosphate 
DTT   Dithiothreitol 
ECL   Enhanced chemiluminescence 
EGFP   Enhanced green fluorescent protein 
FCS   Fetal calf serum 
Fw   Forward 
Fig   Figure 
GFP   Green fluorescent protein 
HAV   Hepatits A virus 
 
 
  
HEV   Hepatitis E virus 
HRP   Horseradish peroxidase 
IEM   Immuno electron microscopy 
IP   Immuno precipitation 
Kb   Kilo base  
kDa   Kilo Dalton 
LB   Luria-Bertani broth 
MOI   Multiplicity of infection 
NCBI   National Center for Biotechnology Information 
NC   Nucleocapsid 
NLS   Nuclear Localization Signal 
NES   Nuclear Export Signal 
OD   Optical density (absorbance/extinction) 
ORF   Open reading frame 
PAGE   Polyacrylamide gel electrophoresis 
PBS   Phosphate-buffered saline 
PI   Post infection 
RIPA   Radioimmunoprecipitation assay 
rpm   revolutions per minute 
Rev   Reverse 
RT   1. reverse transcriptase 
   2. reverse transcription 
   3. room temperature 
TEMED  N,N,N’,N’-tetramethylethylenediamine 
Tris   tris(hydroxymethyl)aminomethane 
WB   Western Blot 
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  Preface 
1. Preface 
Positive stranded RNA viruses cause various viral based diseases in human beings. 
This includes some of the most devastating epidemics over the last few centuries. 
Viruses that infect mammalian cells must replicate before the host immune system 
defenses shut down virus production and/or destroy the infected cell. RNA viruses 
are comparatively simple with regard to their genomic organization. Plus strand RNA 
viruses often encode very few proteins (mostly less than 10) in which mostly 
associated with its structure. RNA viruses also face the same challenges as 
genetically complex viruses in that they must temporarily evade the immune 
response until viral replication and egress takes place (Roulston et al., 1999).  
 
Capsid proteins form major structural component of virus. They are involved in 
nucleic acid binding and recognized function involves packaging genetic material of 
virus into protective structures called nucleocapsids (NC). NC consists of several 
oligomeric structural subunits made of proteins called protomers. The observable 3-
dimensional morphological subunits, which may or may not correspond to individual 
proteins, are called capsomeres. Capsid proteins are arranged in a manner which 
provides maximal contact among subunits and structural units. The repetitive 
interactions among a limited number of proteins results in a regular structure, with a 
symmetry that is determined by the spatial patterns of the interactions (Urbanowski 
et al., 2008). 
 
RNA viruses are enveloped like Dengue virus, Hepatitis C virus, Yellow fever virus 
Influenza virus, Measles virus, Rabies virus, Alphavirus etc. or non-enveloped like 
Poliovirus, Rhinovirus, Enterovirus, Norwalk virus, Hepatitis E virus etc (Carstens & 
Ball, 2009; Fauquet & Fargette, 2005). Here, some of the functions associated with 
viral capsids are further dissected in two viruses, Hepatitis E virus, a non-enveloped 
virus of Hepeviridae and Chikungunya virus, an enveloped virus of Togaviridae 
family. 
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2. Hepatits E virus (HEV) 
2.1. Introduction 
The Hepatitis E virus is an important cause of morbidity and mortality in the regions 
of the world where fecal contamination of the environment and drinking water are 
common. The first well-characterized HEV epidemic was reported in Delhi, India, in 
1955. The symptoms caused by HEV are typically characterized by a self-limiting 
acute hepatitis with low mortality (Krawczynski et al., 1999; Mast et al., 1996). 
However, severe hepatitis has been reported in pregnant women with up to 31.1% 
mortality (Boccia et al., 2006; Guthmann et al., 2006). HEV is transmitted enterically 
and can cause large outbreaks with several thousands of people involved (Fig. 1) 
(Chandra et al., 2008; Jameel, 1999).  
 
 
Figure 1: HEV endemic areas and global seroprevalence. Marked in red are areas in which 
>25% of acute viral hepatitis is due to HEV. Superimposed on this map are seroprevalence 
rates of HEV from various countries, determined in independent studies (Chandra et al., 2008). 
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2.1.1. Taxonomy of HEV 
Compared to other non-enveloped calcivuruses, HEV is slightly smaller eventhough 
its sedimentation coefficient in sucrose and the buoyant density are similar. In 
addition, there exists a superficial resemblance between HEV genome organization 
and that of viruses belonging to the caliciviridae, in which the non-structural 
polypeptides are located towards the 5’ end and the structural polypeptides are 
located towards the 3’ end (Berke et al., 1997). The major change in genome 
organization is the location of ORF3 protein. In HEV, ORF3 is located between 
ORF1 and ORF2 (Fig. 2), where as a caliciviral protein corresponding to HEV-ORF3 
is located at the 3’ end of the viral genome (Jiang et al., 1993). In case of HEV, it 
shows the presence of a cap structure at the 5’ end of its genome (Kabrane-Lazizi et 
al., 1999) whereas viruses of caliciviridae family have protein linked to the 5’ end of 
the genome. With its homologous regions across the genome and with the presence 
of sub-genomic RNA, it was proposed to be a non-enveloped alpha-like virus (Tam 
et al., 1991). Sequence analysis of the non-structural proteins RNA dependent RNA 
polymerase (RdRp) and helicase sequences of HEV and other positive-strand RNA 
viruses shows that they are phylogenetically related to rubella virus (Togaviridae 
family) and a plant furovirus (Beet necrotic yellow vein virus) (Koonin et al., 1992). 
However, HEV has recently been classified as the prototype member in the 
Hepevirus genus of the family Hepeviridae (Chandra et al., 2008). 
2.1.2. Molecular biology of HEV 
HEV is a positive-stranded RNA virus of ~7.5 kb containing three overlapping open 
reading frames (ORFs) (Purdy et al., 1993). ORF1 (nt. 28 to 5107) encodes a 186 
kDa polyprotein (Fig. 2) and gets processed (Sehgal et al., 2006). The four 
conserved domains that code for enzymes in ORF1 includes methyltransferase 
(MeT), RNA helicase, a cysteine protease and RNA dependent RNA polymerase 
(RdRp) (Ansari et al., 2000; Koonin et al., 1992). ORF2 (nt. 5147 to 7126) encodes 
the viral capsid, a 88 kDa glycoprotein (Jameel et al., 1996) that is glycosylated at 
Asn 310 position (Zafrullah et al., 1999) and is stabilized under acidic pH (Zafrullah 
et al., 2004). ORF3 encodes a protein of 13.5 kDa (Jameel et al., 1996), which is 
phosphorylated at Ser 80 (Zafrullah et al., 1997). ORF3 is is shown to interact with 
4 
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non-glycosylated forms of ORF2 (Tyagi et al., 2002) and is proposed to have a role 
in modulation of cell signaling by binding to SH3 domains (Korkaya et al., 2001). 
 
 
 
Figure 2: HEV genome and the proteins it encodes.  
2.1.3. Structure of HEV 
HEV is a small spherical, non-enveloped virus, approximately 27-31 nm in size. 
Immuno Electron Microscopy (IEM) identified HEV, for the first time, in feces of 
patients with hepatitis and from experimentally infected animals (Feinstone et al., 
1973). The first immune-electron micrograph of HEV isolated from the stool of a 
patient infected with HEV showed that hepatitis E virions were spherical and non-
5 
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enveloped, containing surface spikes as well as cup-like indentations, similar to 
caliciviruses (Bradley et al., 1987; Feinstone et al., 1973). Virions isolated from 
stools and bile of infected animals had a size variation ranging from 27 to 32, 34 and 
some times 38 nm with a mean diameter of 32.3 nm (Bradley et al., 1988) (Fig. 3, 
4A). Compared to HAV, the size of HEV particles were distinctly larger i.e. 27-29nm 
versus 29-31nm, (Ticehurst et al., 1992). Structure of HEV-like particle at a 
resolution of 3.5-Å shows that the capsid protein contains 3 linear domains that form 
distinct structural elements: S, the continuous capsid; P1, 3-fold protrusions; and P2, 
2-fold spikes (Guu et al., 2009). Capsid protein shows different folding at the 
protruding and middle domains compared to the members of the families of 
Caliciviridae and Tombusviridae, whereas the shell domain shared the common 
folding. HEV has high resistant towards changes in pH and thus makes it to survive 
in the gastrointestinal environment causing infection (Zafrullah et al., 2004). 
 
Figure 3: Hepatitis E virus Particle. The three-dimensional structure of a self-assembled, 
recombinant HEV particle has been solved to 22 A° resolution by cryo-electron microscopy 
and three-dimensional image reconstruction (Panda et al., 2007). 
 
2.1.4. HEV ORF2 
Seacond ORF of HEV (ORF2) constitutes the structural polypeptide of the virus. 
Analysis of the amino acid sequence (aa) of ORF2 indicated a large hydrophobic 
domain at the N-terminal followed by region enriched in basic amino acids 
associated with RNA binding. Hydrophobic region of HEV ORF2 has a typical signal 
sequence and contain potential cleavage site (PA/PPP) (Tam et al., 1991). This 
region is involved in virion maturation and also associated with endoplasmic 
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reticulum transport. ORF2 also has arginine rich region between residues 22 and 
322, which makes 10% of aminoacids. These also make isolelectric point of 10.35 
for the first half of protein. Due to this highly basic charge, this region is involved in 
the encapsidation of HEV RNA (Surjit et al., 2004). HEV ORF2 being the main 
structural protein also constitute the main antigenic protein making it to be used for 
detection as well as region for designing vaccine. 
2.1.5. HEV in swine  
Complete sequence of HEV was published in 1991 for a Burmese strain (Tam et al., 
1991) this sequence covered greater than 93% nucleotide identity along with other 
Asian isolates including India, China, Nepal and Pakistan (Aye et al., 1993; Gouvea 
et al., 1998; Panda et al., 2000; Tsarev et al., 1992; van Cuyck et al., 2003). 
Compared to Mexican isolate, Burmese isolate is slightly different and forms 
seacond genotype. Isolates found in in the United States and European countries 
including Austria, Greece, Italy, Spain and the United Kingdom as well as Argentina, 
where HEV is not endemic forms the third group HEV genotype (Pina et al., 1998; 
Schlauder et al., 1998; Schlauder & Mushahwar, 2001; Worm et al., 1998; Zanetti & 
Dawson, 1994);(Fig. 4). 
 
HEV was suggested to be a zoonosis after it was experimentally transmitted to 
domestic pigs (Balayan et al., 1990). Sequence alignment of HEV strains US-1 and 
US-2 shows a high sequence similarity with swine HEV. Both these sequences 
shared more than 97% amino acid homology with swine HEV covering ORF1 and 
ORF2. Other than that, all these strains belong to HEV genotype 3. Human US-2 
strain was also capable of infecting swine. There is also report in which cross-
species infection occurs upon inoculating rhesus monkeys with swine HEV. All these 
data provides experimental evidence for cross-species infection with swine HEV and 
shows the possibility of pigs and other animals being a natural reservoir of HEV. 
Thus some of these HEV infections can be of zoonotic origin. Since the discovery of 
swine HEV, many other swine HEV isolates has been reported and sequenced. 
These include Argentina, Australia, Brazil, Canada, China, India, Indonesia, Japan, 
Korea, Kyrgyzstan, New Zealand, Spain, Sweden, Taiwan, Thailand, the United 
Kingdom (Lu et al., 2006) and Mongolia, in addition to the United States (Lorenzo et 
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al., 2007). High prevelance of HEV in wild boar population has been reported in 
Germany (Adlhoch et al., 2009; Kaci et al., 2008; Schielke et al., 2009) Various case 
studies with HEV have been reported in Germany on patients with close contact to 
animals which did not had a recent travel history outside Germany (Brost et al.) Even 
though antibodies against HEV have been reported in domesticated pigs (Baechlein 
et al., 2009) no report has been published on the presence of viral RNA.  
 
 
Figure 4: HEV and its genotypes. (A) Electron micrograph showing HEV particles. (B) A 
phylogenetic tree showing the distribution of human and swine HEV isolates (Chandra et al., 
2008). 
 
2.1.6. Cloning and expression of HEV ORF2 in various 
expression systems, ORF2 as a vaccine candidate 
HEV capsid or ORF2, which forms the outer cover of virus, has been proposed as a 
region for future vaccines (Acharya et al., 2003; Robinson et al., 1998). ORF2 has 
been expressed in vitro through coupled transcription and translation system as well 
as in heterologous expression systems including E.coli (Panda et al., 1995), 
8 
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mammalian cells using plasmids (Jameel et al., 1996), alphavirus vectors (Torresi et 
al., 1999; Torresi et al., 1997), baculovirus expression system (Robinson et al., 1998; 
Sehgal et al., 2003), and in recombinant vaccinia virus (Carl et al., 1994). HEV ORF2 
gets translated to a protein of MW 72000 daltons carrying a putative signal sequence 
and potential sites for glycosylation (Jameel et al., 1996; Tam et al., 1991). 
Expression of ORF2 in mammalian cells (COS-1 and HepG2) using plasmid-based 
expression resulted in a glycoprotein of MW 88000 daltons that was shown to be 
expressed intracellularly, as well as on the cell surface, containing the potential to 
form non-covalent homodimers (Jameel et al., 1996). Multiple ORF2 species were 
observed in both plasmid-based expression and Semliki Forest virus expression 
system (Torresi et al., 1997) with molecular masses estimated as 72,–74, , 79,–84, 
kDa (gPORF2), 84–88 kDa (ggPORF2), with the larger size of the proteins 
corresponding to their glycosylation status (Jameel et al., 1996; Zafrullah et al., 
1999). Glycosilation status of ORF2 was confirmed by endoglycosidase H and 
tunicamycin treatments. This is further proved when ORF2 was pulse chased and 
protein of 82, 84, and 88 were observed. This shows that ORF2 is first translated into 
a mature high Mw protein and gets processed to mature form by proteases and then 
gets glycosylated. The glycosylation sites were investigated by mutational analysis 
(Zafrullah et al., 1999). 
 
It is widely accepted that a successful production of HEV vaccine is attainable as 
HEV has only one serotype. As HEV cell culture system is not robust inactivated or 
attenuated vaccines are not feasible. High-risk groups to HEV include people living 
in HEV-endemic areas, travelers visiting these areas and pregnant women. This 
means that vaccines against HEV will have world wide acceptability. One of the 
earliest reported study utilizing recombinant protein to induce antibody response to 
HEV illustrated the importance of ORF2 protein in immunity against HEV (Purdy et 
al., 1993).  
2.1.7. Infectious system of HEV  
Various groups have tried to propagate HEV in vitro in various cell lines (Divizia et 
al., 1999; Huang et al., 1992; Kazachkov Yu et al., 1992; Meng et al., 1997; Wei et 
al., 2000), still an efficient cell culture system has not been reported. Most of the 
9 
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reports made infectious cDNA clones replicating in non-human primates or pigs. 
These were also not efficient in HEV propagation. This is mainly because of the virus 
inability to spread in cell culture system (Emerson et al., 2004; Emerson et al., 2001; 
Graff et al., 2005; Huang et al., 2005; Panda et al., 2000). One of the promising 
construct developed using PLC/PRF/5 and A549 cells involve genotype 3 HEV 
(strain JE03-1760F), obtained from a fecal specimen from a Japanese hepatitis E 
patient (Yamada et al., 2009); (Fig. 9). This system was further used by us to study 
the HEV propagation and egress.  
 
Figure 5: A proposed model for hepatitis E virus replication and egress. Drawn according to (Jameel, 
1999). 
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2.2. Materials and Methods 
2.2.1. Materials 
2.2.1.1. Devices 
  
Camera Olympus, Hamburg 
Cell incubator Type B 5060 EC CO2, Heraeus, Hanau 
Labotect, Göttingen 
Centrifuge Eppendorf, Hamburg 
Biofuge fresco, Heraeus 
AllegraTM 21R, Beckman Coulter, 
Fullerton USA 
Electroblotting chamber Bio-Rad, München 
Electrophoresis chamber For agarose gels: Wide mini sub cell, 
Bio-Rad, München 
For polyacrylamide gels: mini protean 3 
Bio-Rad, München 
Heating block DRI-BLOCK DB3, Techne, Jahnsdorf 
Incubator 
 
 
Laminar Flow  
Heraeus, Hanau, Arbeitsbank, BDK 
Luft- und Reinraumtechnik 
Sonnenbuhl-Genkingen 
Arbeitsbank Heraeus-Kendro, Hanau 
Minishaker  MS2, IKA, Staufen 
Microscopes  Axiovert 25, Carl Zeiss, Göttingen 
Axiovert 40 Carl Zeiss, Göttingen 
Microwave oven Micro-Chef FM 3915 Q, Moulinex 
PCR Thermocycler Personal Cycler, Biometra, Göttingen 
iCycler, Bio-Rad, München 
pH-meter pH 211, Microprocessor pH meter, 
Hanna-instruments, USA  
Pipettors Finn pipettors (5-40 µl, 40-200 µl, 200-
1000 µl), Labsystems, Finnland 
Eppendorf pipettors (0.5-10 µl, 10-100 
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µl, 200-1000 µl), Eppendorf, Hamburg 
Power supply Power Supply Model 3000 X, Bio Rad, 
München 
Shaker  Vortex Genie, Bender & Hobein, 
München 
Sonicator Bandelin Electronic, Berlin 
Spectrophotometers Smart SpecTM3000, Bio-Rad, 
München 
Spectra, Tecan, Crailsheim 
Table top centrifuge Centrifuge 5415 C, Eppendorf, 
Hamburg 
UV transilluminator Bio-View, Biostep, Jahnsdorf 
Water bath GFL1086, GFL, Wunstorf 
2.2.1.2. General material 
 
Cryo tubes, 2 ml Greiner, Frickenhausen 
Culture dishes, 35 mm diameter Becton Dickinson, Heidelberg 
Culture dishes, 90 mm diameter Nunc, Wiesbaden 
Culture flasks, 80 cm2 Nunc, Wiesbaden 
Filter paper (Whatman 3 MM) Whatman, Göttingen 
Filtration units (sterile Millex units) Millipore, Eschborn 
Glass pipettes, 1 ml, 5 ml, 10 ml Hirschmann, Eberstadt 
Glass ware Schott, Mainz ; Brand, Wertheim 
Syringes, 20 ml, sterile Braun, Melsungen 
Nitrocellulose membrane  Bio-Rad, München 
Amersham, Freiburg 
PCR tubes (0.2 ml)  PeqLab, Erlangen 
Petri dishes (AD94/H16 mm) Roth, Karlsruhe 
Pipette tips Braun, Melsungen 
Plastic tubes, 14 ml Greiner, Frickenhausen 
Plastic tubes, 50 ml Nunc, Wiesbaden 
Plastic reaction tubes, 1.5 ml Brand, Wertheim 
Pursept®-A disinfectant solution Merz via Fischer, Frankfurt a. m 
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Safe Skin Satin Plus powder-free latex 
gloves 
Kimberly Clark, Koblenz-Rheinhafen 
Sterile filters (0.2 µm and 0.45 µm) Renner GmBH, Dannstadt 
Sterile single use serological pipets (10 
ml) 
Falcon via Multimed, Kirchheim Teck 
X-ray film Amersham, Freiburg 
2.2.1.3. Chemicals 
Ammonium peroxodisulfate (APS) Fluka, Steinheim 
Bradford assay dye reagent Bio-Rad, München 
Bromophenol blue  Fluka, Steinheim 
BSA Sigma-Aldrich, Steinheim 
Calcium chloride dehydrate E. Merck, Darmstadt 
Coomassie brilliant blue R 250 Sigma-Aldrich, Steinheim  
Dimethylsulfoxide (DMSO)  Sigma-Aldrich, Steinheim 
EDTA Roth, Karlsruhe 
Glycerol Roth, Karlsruhe 
Glycine  Roth, Karlsruhe 
Mercaptoethanol Sigma-Aldrich, Steinheim 
MnCl2 Sigma-Aldrich, Steinheim 
NaCl Sigma-Aldrich, Steinheim 
NaHCO3 Sigma-Aldrich, Steinheim 
PageRulerTM prestained protein ladder MBI Fermentas 
Potassium chloride E. Merck, Darmstadt 
SDS Fluka, Steinheim 
Sucrose Roth, Karlsruhe 
N,N,N’,N’-Tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich, Steinheim 
 
Protease inhibitor cocktail EDTA free Thermo Scientific, USA 
RIPA buffer Thermo Scientific, USA 
Tris Roth, Karlsruhe 
Tween® 20 Fluka, Steinheim 
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2.2.1.4. Kits 
Enhanced chemiluminescence (ECL) 
detection reagent 
Amersham, Freiburg 
high pure viral RNA kit Roche, Berlin 
QIAquick gel extraction kit Qiagen, Hilden 
QIAquick PCR purification kit Qiagen, Hilden 
RNeasy RNA isolation kit Qiagen, Hilden 
QIAprep Spin Miniprep Kit Qiagen, Hilden 
QIAGEN Plasmid Maxi Kit Qiagen, Hilden 
MEGAscript® T7 Kit Ambion, Applied biosystems, California, 
USA 
m7G Capping System  Epicentre Biotechnologies, USA 
2.2.1.5. Reagents for molecular biology 
Agarose PeqLab, Erlangen 
BSA (100x) New England Biolabs, Frankfurt a.M. 
Dithiothreitol (DTT), 0.1 M Gibco BRL, Karlsruhe 
GeneRuler 1 kb DNA ladder MBI Fermentas, St. Leon-Rot 
GeneRuler 100 bp DNA ladder plus MBI Fermentas, St. Leon-Rot 
Deoxyribonucleoside triphosphate 
(dNTP;  
10 mM each) 
PeqLab, Erlangen 
Ethidium bromide Sigma-Aldrich, Steinheim 
PCR primers TIB MOLBIOL GmbH, Berlin 
Eurofins MWG Operon, Ebersberg  
RNAsin ribonuclease inhibitor (40 U/µl) Promega, Mannheim 
T4 DNA Ligation Buffer (10x) MBI Fermentas, St. Leon-Rot 
New England Biolabs, Frankfurt a.M. 
Turbofect transfection reagent Fermentas GmbH 
TransIT®-mRNA Transfection Kit Mirus Bio LLC 
Madison, USA 
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2.2.1.6. Enzymes for molecular biology 
Restriction enzymes New England Biolabs, Frankfurt a.M. 
Calf intestine alkaline phosphatase 
(1U/µl) 
New England Biolabs, Frankfurt a.M. 
HotStart Taq DNA polymerase Qiagen, Hilden 
MLV Reverse Transcriptase Qiagen, Hilden 
Pfu turbo High-Fidelity DNA polymerase Stratagene, Amsterdam 
RNAse A Qiagen, Hilden 
T4 DNA ligase MBI Fermentas, St. Leon-Rot 
New England Biolabs, Frankfurt a.M. 
2.2.1.7. Constituents and reagents for bacterial and mammalian cell 
cultures 
Antimycotic/antibiotic Sigma-Aldrich, Steinheim 
Carbenicillin, disodium salt  Roth, Karlsruhe 
Dulbecco’s modified Eagle’s medium 
(DMEM) powder lacking pyruvate and 
NaHCO3  
GibcoBRL, Karlsruhe 
Fetal calf serum (FCS) Biochrome, Berlin 
Kanamycin  Applichem, Darmstadt 
LB-agar powder Fluka, Steinheim 
LB-broth powder Fluka, Steinheim 
Penicillin G, potassium salt Serva, Heidelberg 
Superoptimal broth, catabolite repression 
(SOC) medium 
Novagen, Schwalbach/Ts. 
Streptomycin sulfate Serva, Heidelberg 
Trypsin   ICN, Eschwege 
2.2.1.8. Antibodies 
His Probe, (rabbit) polyclonal antibody Santacruz Biotechnology, USA 
Anti-Mouse IgG (Goat) HRP conjugated Santacruz Biotechnology, USA 
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Anti-Rabbit IgG (Donkey) HRP 
conjugated 
Santacruz Biotechnology, USA 
2.2.1.9. Bacterial strains 
Top10 E.coli cells Invitrogen, Karlsruhe  
BJ5183 E.coli cells Stratagene, Amsterdam 
NovaBlue SinglesTM competent cells Novagen, Schwalbach/Ts. 
Bl21 cells  Invitrogen, Karlsruhe 
2.2.1.10. Mammalian cell lines 
HEK 293 cells American Type Culture Collection 
(ATCC) 
HuH7 cells 
 
PLC/PRF/5 
American Type Culture Collection 
(ATCC) 
American Type Culture Collection 
(ATCC) 
2.2.1.11. Vectors 
pcDNA 3.1/v5-His-TOPO Invitrogen, Karlsruhe 
pET-28a+ 
pSK-HEV-2 
 
pAdTrack-CMV 
pJE03-1760/wt 
Merck KGaA, Darmstadt 
Kind gift of S. Emerson and R. Purcell, 
NIH, Maryland 
Addgene, Cambridge, USA 
Kind gift of Hiroaki Okamoto, Yakushiji, 
Japan 
2.2.1.12. Primers list 
Name of the primer Sequence 
HE040 5’-cccttrtcctgctgagcrttctc-3’ [r = a or g) 
HE044 5’-caagghtggcgytckgttgagac-3’ [h=a, t, or c; y =t or c; 
and k = g or t] 
HE110-2 
 
5’-gytckgttgagacctcyggggt-3’, 5’-
gytckgttgagaccacgggygt-3’, 5’-gytckgttgagacctctggtgt-
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HE041 
3’ 
5’-ttmacwgtcrgctcgccattggc-3’ [m = a or c, w =a or t] 
HEV ORF2 fwd primer 5’-ccatgggcatgcgccctcggcctattttg-3’ 
HEV ORF2 rev primer 5’-ctcgagtaactcccgagttttacccac-3’ 
Bgl2f2_fw 5’-agatctatgcgccctcggcctattttg-3’ 
Sal1f2_rev 5’-gtcgacaactcccgagttttacccaccttc-3’ 
250 fwd 5’-cccgggtaatacgactcactatagggaggcagacca 
catatgtggtcg-3 
250 rev  5’-ccatggtcagctcattatggataacacgctggatgg-3’ 
2.2.2. Sample collection 
The swine serum samples were collected in Mecklenburg-Vorpommern, 
Brandenburg, Nordrhein-Westfalen and Niedersachsen with the help of Dr. K. 
Depner, Friedrich-Loeffler-Institut, Greifswald - Insel Riems. 
2.2.3. RNA isolation 
Viral RNA from sera was isolated using Roche high pure viral RNA kit according to 
the manufacture’s instruction. Briefly, the sample was mixed with working solution 
containing carrier RNA and centrifuged in a table top centrifuge (Eppendorf). After 
washing, the viral RNA was eluted using an elution buffer and was stored at -80 °C 
until use. 
2.2.4. Detection of HEV by nested RT-PCR 
RNA isolated from serum was reverse transcribed with MLV reverse transcriptase 
(Invitrogen) and an antisense primer (primer HE040; 5’-cccttrtcctgctgagcrttctc-3’ [r = 
a or g) specific for the HEV ORF2 as described before (Mizuo et al., 2002) and was 
subjected to nested PCR. A region of the ORF2 sequence was amplified with the 
primer pair HE044 (sense primer; 5’-caagghtggcgytckgttgagac-3’ [h=a, t, or c; y =t or 
c; and k = g or t]) and HE040 in the first round and HE110-2 (sense primer; mixture 
of three sequences, 5’-gytckgttgagacctcygggg t-3’, 5’-gytckgttgagaccacgggygt-3’ and 
5’-gytckgttgagacctctggtgt-3’) and HE041 (antisense primer; 
5’ttmacwgtcrgctcgccattggc3’ [m = a or c, w =a or t]) in the second round (ORF2 
PCR). The PCR amplification was carried out for 35 cycles in the first round (94 °C 
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for 30 s [an additional 2 min was used in the first cycle], 55 °C for 30 s, 72 °C for 75 s 
[an additional 7 min was used in the last cycle]) and then for 30 cycles in the second 
round under the same conditions used for the first round; here it was further 
extended for 60 s. PCR product size from the first amplification was 506 bp, and that 
of second round was 458 bp. The amplified products were analyzed on a 1.5% 
agarose gel, and photographed under UV-transilluminator (Bio-View). 
2.2.4.1. Sequence analysis of PCR products 
The amplification product from sample 3205-45 was column purified using Qiagen 
PCR purification kit according to manufacture instructions and sent for sequencing 
(GATC Biotech) for both forward and reverse directions. The sequences were 
analyzed for the similarity using Basic Local Alignment Search Tool (BLAST) 
http://blast.ncbi.nlm.nih.gov/Blast.cgi. Tree view of the sequence was constructed 
using the tool BLAST Tree view (http://blast.ncbi.nlm.nih.gov/ 
blast/treeview/treeView.cgi). 
2.2.5. Expression analysis of HEV ORF2, using mammalian 
expression system 
2.2.5.1. Cloning of HEV ORF2 to pcDNA™3.1D/V5-His-TOPO 
HEV ORF2 was amplified using primers, Hev ORF2 fwd primer 5’-
ccatgggcatgcgccctcggcctattttg-3’, HEV ORF2 rev primer 5’-
ctcgagtaactcccgagttttacccac-3’ using HEV clone pSK-HEV-2 (GenBank accession 
no. AAF444002, Kind gift of S. Emerson and R. Purcell, NIH, Maryland) as template 
and amplified using PFU turbo (Stratagene) polymerase enzyme. The PCR product 
was A-tailed using taq polymerase (Invitrogen) by incubating it with 0.5 units of taq at 
72 °C for 10 min. It was further gel purified and cloned to pcDNA™3.1D/V5-His-
TOPO vector (Invitrogen) (Fig. 6). Positive clones were screened by restriction 
digestion and sequencing at both forward and reverse directions. 
2.2.5.2. Transfection and protein extraction 
HEK293 cells were used for transfection using turbofect transfection reagent 
(Fermentas), according to manufacturer’s ’ instructions. 48 hours post transfection, 
cells were washed with PBS, and incubated with RIPA buffer and protease inhibitor 
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cocktail EDTA free (Thermo Scientific), for 10 min and lysed with RIPA buffer. The 
lysate was centrifuged at 13,000 RPM for 10 min and the supernatant was used for 
protein estimation. 
2.2.5.3. Protein assay (Bradford assay) 
Protein concentration was assayed using Bio-Rad Bradford dye reagent concentrate 
and was performed according to Bradford (1976).The reagent was diluted (1:6 in 
water) and was mixed with 10 µl of the sample, which makes a final volume of 1 ml, 
followed by 15 min RT incubation. 96-well plate containing 400 µl reaction mixture 
was analyzed at a wavelength of 595 nm in a microplate reader. The final 
concentration was determined after calculating through standard curve using BSA 
with a range from 10 to 100 µgm. 
2.2.5.4. SDS-PAGE 
SDS PAGE was carried out as described by(Garfin, 1990; Laemmli et al., 1970) with 
the modifications by (Garfin, 1990). 
Solutions 
Acrylamide solution: 29.2% (w/v) acrylamide, 0.8% (w/v) bisacrylamide (Sigma) 
SDS: 10% (w/v) 
APS solution: 10% (w/v) 
TEMED 
Running gel buffer: 0.5 M Tris / HCl, pH 8.8 
Stacking gel buffer: 1.5 M Tris /HCl, pH 6.8 
Electrode buffer: 25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS 
Five-fold concentrated sample buffer: 0.16 M Tris / HCl, 4% (w/v) SDS, 20% (w/v) 
glycerol, 0.38 M mercaptoethanol, 0.008 (w/v) bromophenol blue; pH 6.8  
 
 
 
Preparation of the gels 
The gel size was 8 cm x 10 cm x 1 mm. The stacking gels were prepared with 5% 
acrylamide at pH 6.8, the running gels with 10-12% acrylamide depending on the 
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protein size at pH 8.8. The scheme as shown in table 1: was used for casting the 
gels:  
Table 1: Scheme for casting 10% SDS-PAGE gel 
Solution 10% running gel 5% stacking gel 
30% Acrylamide solution 3.3 ml 0.83 ml 
Running gel buffer 2.5 ml  
Stacking gel buffer  0.63ml 
Water 4.0 ml 3.4 ml 
10% (w/v) SDS 100 µl 50 µl 
TEMED 20 µl 5 µl 
10% (w/v) APS solution 37.5 µl 200 µl 
 
Preparation of the samples 
5X protein sample buffer was added to the samples and filled up with H2O. The 
protein buffer mix was then heated to 95 °C for 5 min. After collecting the 
condensate by brief centrifugation, the samples were loaded to the gel.  
 
Electrophoresis 
Electrophoresis was carried out under constant current 20 mA at RT. When the 
bromophenol blue front had reached the end of the running gel, the process was 
stopped. The gels were either stained with Coomassie Brilliant Blue R 250 or used 
for Western blotting.  
2.2.5.5. Coomassie blue staining of polyacrylamide gels 
 
Solutions 
Staining solution: 50% methanol, 40% H2O, 10% glacial acetic acid and 1% (w/v) 
Coomassie Brilliant Blue R 250 (in water). Destaining solution: Methanol: H2O: 
glacial acetic acid (3:6:1).  
 
Experimental procedure 
Polyacrylamide gels were incubated with staining solution at RT for 10 min, 
afterwards; gels were briefly rinsed with water and transferred to destaining solution. 
Once the blue background had disappeared and single protein bands became 
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visible, the destaining solution was discarded and the gel was washed with ddH2O. 
Protein bands were documented using digital scanner.  
2.2.5.6. Western blot analysis with chemiluminescence detection 
Protein transfer solutions 
Transfer buffer: 25 mM Tris / HCl, 192 mM glycine; pH 9.0 
Ponceau S solution: 0.2% (w/v) Ponceau S in 3% (w/v) trichloroacetic acid 
 
Experimental procedure 
Proteins (30 µg) were separated through discontinuous SDS PAGE. Gels excised 
out were rinsed once with transfer buffer. The protein bands were then transferred 
from the gel to a nitrocellulose membrane using a modification of the protocol 
described by Burnette (1981) as detailed below. 
Nitrocellulose was packed as a “sandwich” containing 3 pieces of filter paper with gel 
and nitrocellulose membrane in the middle. This was further used for transfer using 
XCell Blot module (invitrogen). Transfer was carried out at 120 mA at 4 °C for 1 h.  
 
Detection of protein bands with the enhanced chemiluminescence (ECL) 
reagent 
 
Solutions 
Washing buffer: 20 mM Tris / HCl, 150 mM NaCl, 0.02% (v/v) Tween 20; pH 7.4 
(PBST) 
Blocking solution: 5% milk powder in PBST 
Substrate solution: 250 µl ECL solution I + 6 µl ECL solution II (Amersham) 
 
Experimental procedure 
The membrane was incubated overnight with 10 ml blocking solution at 4 °C to block 
unspecific binding. After blocking the membrane was further incubated with 
appropriate antibodies. Incubation was carried out from 1h to overnight. The 
membrane was washed three times for 5 min with 25 ml TBST, followed by 
incubation with 20 ml of the secondary antibody solution for 1 hour to overnight. The 
membrane was washed again three times for 5 min with 25 ml TBST, rinsed briefly 
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with PBS and then the ECL detection solution was added dropwise to cover the 
membrane. After 2 min, the solution was removed and the membrane placed in a 
exposure casette. An X-ray film (Amersham) was later exposed to the membrane for 
different time-ponts in the exposure cassette. The film was developed in an X-ray 
film developing machine.  
 
Figure 6: Vector map of clone HEV ORF2 in pcDNA 3.1/V5-His-TOPO 
2.2.6. Bacterial expression system 
2.2.6.1. Cloning of HEV ORF2 into pET-28a 
PcDNA-ORF2 was digested with BamHI and XhoI to sub-clone into E. coli 
expression vector pet28a (Novagen) (Fig. 7). Positive clones were screened by 
restriction enzyme digestion.  
2.2.6.2. Protein purification 
N-terminal His-tagged pet28a-ORF2 was transformed to Bl21 cells (Invitrogen). The 
bacterial culture was grown at 37 °C until OD600 had reached 0.6, induced with 
IPTG at a concentration of 1 mM and incubation continued for additional 6 h. The 
cells were pelleted and resuspended in 6 ml of buffer containing PBS and lysed by 
sonication for 3 min. The cell lysate was spun at 5,000 RPM for 20 min and 
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supernatant was discarded. The pellet which contained HEV ORF2 as inclusion body 
was resuspended in 5 ml of buffer containing 8 M urea in PBS. Solubilized inclusion 
body was further centrifuged and imidazole was added to the supernantant at a final 
concentration of 10 mM. Precharged and prewashed Ni-NTA beads (Invitrogen) of 
0.6 ml of bed volume were mixed with the lysate at RT for 1 h. It was then loaded to 
the column and washed with 50 ml of PBS containing 20 mM imidazole and 8 M 
urea. Protein bound to the column was eluted using elution buffer containing PBS, 8 
M urea, and 300 mM imidazole. Eluents were analyzed by SDS-PAGE and 
confirmed by Western blot using anti-His or anti-ORF2 antibodies. 
 
Figure 7: Vector map of pET-28a-ORF2 
2.2.7. Adenovirus expression system 
Recombinant adenovirus was synthesized using the AdEasy system (Stratagene); 
(He et al., 1998). Briefly, HEV ORF2 was amplified by PCR from full-length HEV 
clone pSK-HEV-2 with primers bgl2f2_fw 5’-agatctatgcgccctcggcctattttg-3’ and 
Sal1f2_rev 5’-gtcgacaactcccgagttttacccaccttc-3’ and cloned into the vector, 
pAdTrack-CMV shuttle plasmid. Clones were verified by sequencing in both forward 
and reverse directions. Shuttle vector pAdTrack-CMV-F2 was linearized with pmeI 
and electroporated to BJ5183 E. coli cells.  
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2.2.7.1. Production of adenovirus 
PacI-digested recombinant adenoviral DNA (4 ug) was transfected in HEK293 cells 
in T-25 flask using Turbofect (Fermentas) according to manufacturer’s instructions 
as shown in Fig. 8. Transfected cells were monitored in DMEM containing 10% FCS 
for cytopathic effects (CPE), which were observed by approximately 6 to 10 days 
post-transfection. Cells were harvested and exposed to three cycles of freezing in 
dry ice and thawing at 37 °C water bath to release the virions from the cells. The 
supernatant was aliquoted in eppendorf tubes and stored at -80 °C until use. 
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Figure 8: Schematic representation of the AdEasy technology. Drawn according to (He et al., 
1998; Luo et al., 2007) 
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2.2.7.2. Virus generation, infection of HEK-293 cells with 
recombinant adenovirus 
HEK-293 cells were plated in 25-cm2 tissue culture flasks (Nunc) at 80–90% 
confluency (approximately 3 × 106 cells per flask in 7 ml complete DMEM) 6–15 h 
before infection. They were then infected by adding viral supernatant from primary 
transfection. Viral infection was observed using the tracking protein GFP. CPE or cell 
lysis will be seen at 2- 3 days post-infection. For rest of the experiments cell were 
infected at an MOI of 10. Cells were harvested once the cells have rounded up and 
most of the cells detached (3 to 4 days). Infected cells were used for further 
experiments or stroed at -80 °C until use. 
2.2.7.3. Total RNA extraction  
Total cellular RNA was isolated using RNeasy RNA isolation kit from Qiagen. The 
cells (approximately 107 cells) were collected by trypsinisation and pelleted by brief 
centrifugation. The cell pellet was disrupted by adding 600 µl of buffer RLT and 
repeated pipetting. Then 1 volume of 70% ethanol was added to the lysate, and the 
solution was mixed well by pipetting. The sample was transferred to the supplied 
RNeasy spin column and centrifuged (13,000 rpm, RT, 15 s). The flow-through was 
discarded and the membrane of the column was washed by the addition of 700 µl of 
buffer RW1 and a brief centrifugation (13,000 rpm, RT, 15 s). The flow-through was 
discarded and the membrane of the column was washed again with buffer RPE 
(ethanol added) by centrifugation (13,000 rpm, RT, 1 min). This was followed by brief 
centrifugation (13,000 rpm, RT, 1 min) to prevent ethanol carry-over and to dry the 
column. The column was subsequently placed in a 1.5 ml sterile microfuge tube, and 
the total RNA was eluted with 50 µl of RNase-free water by centrifugation (13,000 
rpm, RT, 1 min). The concentration of isolated RNA was measured photometrically  
2.2.7.4. Photometric determination of nucleic acid concentration 
The concentration of RNA was determined photometrically. For this, the absorbance 
(OD) was measured at a wavelength of 260 nm in biophotometer (eppendorf). The 
solvent in which the sample was diluted was used as a reference (blank). An OD260 
value of 1 corresponded to a concentration of 40 µg/ ml. The sample volume was 3 
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µl. To estimate the purity of samples, the OD260/OD280 ratio was calculated. A 
protein-free nucleic acid solution was assumed to display a ratio from 1.8 up to 2.0.  
2.2.7.5. Reverse transcription of RNA and PCR 
Total cellular RNA was isolated using RNeasy RNA isolation kit according to the 
manufaturers advice. The reaction mixture for reverse transcription of RNA 
contained 5 mM MgCl2, 10 mM each of dGTP, dATP, dTTP and dCTP. Moloney 
murine leukemia virus reverse transcriptase (MLV RT), 10 pmol antisense primer 
Sal1f2_rev 5,-gtcgacaactcccgagttttacccaccttc-3’, specific for the HEV ORF2 and 1 µg 
total RNA in 50 µl of RT-buffer. All the pipetting were done on ice. The mixture was 
incubated for 1 h at 37 °C, followed by heat inactivation at 95 °C for 5 min. Sample 
with out the addition of RT was used as control. cDNA was then subjected to PCR 
with primers bgl2f2_fw 5’-agatctatgcgccctcggcctattttg-3’ and Sal1f2_rev 5’-
gtcgacaactcccgagttttacccaccttc-3’.  
2.2.8. Propagation of HEV, in vitro transcription 
PJE03-1760F (Fig. 9) plasmid was linearized by digestion with NheI and the 
template was further purified using qiagen QIAquick PCR purification kit. The 
genomic RNA was transcribed with Megascript kit (Ambion) by in vitro transcription 
with T7 polymerase and 4 ribonucleotide solutions (ATP, CTP, GTP, and UTP). 
Transcription reaction products were treated with RNase-free DNase (1U) at 37 °C 
for 20 min, followed by ethanol precipitation and purification of RNA. Purified RNA 
was dissolved in RNase free water. 
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Figure 9: Structure of the infectious HEV construct. Drawn according to (Yamada et al., 2009) 
2.2.8.1. Capping 
For capping, the ScriptCap m7G Capping System (Epicentre Biotechnologies) was 
used according to manufacturer’s protocol. Briefly, 45 µgm of RNA was heat 
denatured by incubating at 65 °C for 10 min and transfered to ice immediately. RNA 
was then mixed with other components containing 10X ScriptCap Capping Buffer, 10 
mM GTP, 2 mM SAM, RNase Inhibitor ScriptCap Capping Enzyme and incubated at 
37 °C for 60 min. After capping, the RNA was again purified by ethanol precipitation 
and redissolved in RNAse free water. 
2.2.8.2. Transfection of HEV RNA 
PLC/PRF/5 cells, grown in culture medium consisting of Dulbecco’s modified Eagle’s 
medium (DMEM), supplemented with 10% (v/v) fetal calf serum (FCS), 100 U/ml 
penicillin G, 100 µgm streptomycin/ml and 2.5 µgm/ml amphotericin B was used for 
transfecting HEV RNA. 3 µgm of the capped RNA was transfected into 60–80% 
confluent cells, in one well of a six-well plate using the TransIT-mRNA Transfection 
kit (Mirus Bio); the transfected cells were incubated at 37 °C. Two days 
posttransfection (dpt.), the culture medium was replaced with 2 ml fresh medium and 
incubated further. Half of the culture medium (1 ml) was replaced afterwards every 
alternative day, containing 50% DMEM and 50% medium 199 (Invitrogen), 2% FCS, 
28 
Chapter 1  Materials and Methods 
30 mM MgCl2, 100 U/ml penicillin G ,100 µgm/ml streptomycin and 2.5 µgm/ml 
amphotericin B. The collected medium was centrifuged at 800 g at 4 °C for 5 min 
and the supernatant was stored at -80 °C until use. At 19 dpt, the cells were splitted 
and seeded in 10 cm dishes and maintained in maintenance media or stored in liquid 
nitrogen. 
2.2.9. Simvastatin treatment and viral RNA isolation 
To look for the effect of simvasatin on virus egresses, simvastatin (Sigma) was 
activated as described (Sadeghi et al., 2000). Briefly simvastatin (4 mg) was 
dissolved in 100 μl of ethanol and to it 150 μl of 0.1 N NaOH was added. The 
dissolved simvastatin containing solution was subsequently incubated at 50 °C for 2 
hours and the pH was brought to 7.0 by HCl. The stock solution was stored at 4 °C. 
This was added to the HEV containing PLC/PRF/5 cells at a concentration of 20 and 
50 µM. Medium was collected after 36 h and stored at -80 °C until use.To monitor 
virus production in transfected cells, HEV RNA was isolated from culture supernatant 
using viral RNA extraction kit (Roche) according to manufacturer’s instruction. RT-
PCR was done with primers 250fwd 5’-
cccgggtaatacgactcactatagggaggcagaccacatatgtggtcg-3’ and 250rev 5’-
ccatggtcagctcattatggataacacgctggatgg-3’. 
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2.3. Results 
2.3.1. Detection of HEV in swine 
HEV has been detected in domesticated pigs in several European countries. 
However, no data is available about German pigs. In order to analyze German pigs 
for the presence of HEV RNA, I screened swine sera obtained from various German 
farms. 
 
Figure 10: RT-nested PCR of HEV RNA from various swine serum isolates using primers 
specific to HEV ORF2 region. HEV clone pSK-HEV-2 is used as positive control. 
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Table 2: Detection of HEV RNA in swine serum using ORF2 specific nested PCR 
No Name of the 
sample 
HEV RNA 
presence 
through 
nested 
PCR 
No Name of the 
sample 
HEV RNA 
presence 
through 
nested PCR 
1 WATER CONTROL Negative 24 320-5 Positive 
2 3205 Positive 25 WATER CONTROL Negative 
3 Positive control Positive 26 Positive control Positive 
4 DNA marker  27 DNA marker  
5 WATER CONTROL Negative 28 ESP44 Negative 
6 ESP19 Positive 29 ESP35 Negative 
7 Positive control Positive 30 ESP27 Negative 
8 DNA marker Negative 31 ESP19 Positive 
9 ESP 61 Negative 32 ESP10 Negative 
10 ESP127 Negative 33 WATER CONTROL Negative 
11 669-10 Negative 34 Positive control Positive 
12 ESP-135 Negative 35 DNA marker  
13 669-2 Positive 36 2.1 Positive 
14 N1181-7 Positive 37 2.2 Negative 
15 730-6 Negative 38 2.3 Negative 
16 668-6 Negative 39 40 Positive 
17 Positive control Positive 40 2.1A Positive 
18 DNA marker  41 2.2B Positive 
19 ESP111 Negative 42 2.3C Negative 
20 ESP 102 Negative 43 040 Negative 
21 ESP 143 Negative 44 040-B Negative 
22 ESP119 Negative 45 WATER CONTROL Negative 
23 215-7 Negative 46 DNA marker  
   47 ESP Negative 
   48 5750 Negative 
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No Name of the 
sample 
HEV RNA 
presence 
through 
nested 
PCR 
No Name of the 
sample 
HEV RNA 
presence 
through 
nested PCR 
49 57529 Negative 71 ESP19-C Positive 
50 Positive control Positive 72 5750 Negative 
51 WATER CONTROL Negative 73 Positive control Positive 
52 DNA marker  74 3205-M Negative 
53 5750-B Negative 75 WATER CONTROL Negative 
54 Positive control Positive 76 DNA marker  
55 WATER CONTROL Negative 77 W1181-7 Negative 
56 DNA marker  78 3205-45 Positive 
57 ESP19-B Positive 79 B4-ESP19 Positive 
58 3205-6 Negative 80 Positive control Positive 
59 PS1 Negative 81 WATER CONTROL Negative 
60 PS2 Negative 82 DNA marker  
61 18/12 Negative 83 WATER CONTROL Negative 
62 3205-B Negative 84 ESP85 Positive 
63 1645 Positive 85 Positive control Positive 
64 WATER CONTROL Negative 86 DNA marker  
65 Positive control Positive    
66 DNA marker     
67 ESP127-B Negative    
68 Positive control Positive    
69 WATER CONTROL Negative    
70 DNA marker     
 
Out of 50 samples analyzed, 16 (32%) were found to be positive for the presence of 
HEV RNA using HEV ORF2 specific nested PCR (Fig. 10 & table 2). This was further 
confirmed by sequencing one of the PCR products: 3205-45. The sequence obtained 
was searched for similarities to HEV using BLAST to find regions of local similarity 
between sequences (Fig. 11). It was found that it is 91% related to its counterpart of 
swine HEV, accession no AB481226.1 (Swine hepatitis E virus genomic RNA, 
complete genome, isolate: swJB-E10). The sequence can be thus put in genotype 3 
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of swine HEV. Though a majority of HEV infections are asymptomatic, sustained 
transmission may lead to the evolution of virulent strains. HEV genotype 3 is very 
widely distributed and a newly evolved strain can cause more far-reaching 
consequences. Swine HEV has been detected in raw pige livers (Yazaki et al., 2003) 
and the sequence analysis shows recombination of swine and human HEV strains 
from patients in the USA, Japan and other countries.  
 
HEV was suggested to be a zoonosis after it was experimentally transmitted to 
domestic pigs (Balayan et al., 1990). Sequence alignment of HEV strains US-1 and 
US-2 shows a high sequence similarity with swine HEV. Both these sequences 
shared more than 97% amino acid homology with swine HEV covering ORF1 and 
ORF2. Other than that, all these strains belong to HEV genotype 3. Human US-2 
strain was also capable of infecting swine. There is also report in which cross-
species infection occurs upon inoculating rhesus monkeys with swine HEV. All these 
data provides experimental evidence for cross-species infection with swine HEV and 
shows the possibility of pigs and other animals being a natural reservoir of HEV. 
Zoonotic transmission of HEV is a major health issue in developed countries which 
doesn’t have report of faecal-oral HEV transmission. Humans who consume 
contaminated pork products and are involved in the rearing of pigs are potentially at 
risk of HEV infection (Matsuda et al., 2003; Tei et al., 2003). Anti-HEV antibodies 
have been detected in many more animal species, including wild boar and deer and 
HEV genotype 3 was identified from a boar in Japan (Sonoda et al., 2004).  
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Figure 11: Showing the BLAST Tree view of sequence amplified from ORF2 region of HEV 
RNA. Unknown sequence with arrow refers to the location of nucleotide sequence of the 
submitted HEVswine isolate. 
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2.3.2. HEV ORF2 expression in various expression 
systems, ORF2 as a vaccine candidate 
2.3.2.1. Mammalian expression system 
HEV ORF2 is expected to be translated into a protein of MW 72 kDa carrying a 
putative signal sequence and potential sites for glycosylation (Jameel et al., 1996; 
Tam et al., 1991). ORF2 expression in mammalian cells (COS-1 and HepG2) using 
plasmid-based expression yielded a glycoprotein of MW 88 kDa that was shown to 
be expressed intracellularly, as well as on the cell surface and formed non-covalent 
homodimers (Jameel et al., 1996). As it was important to analyze the use of ORF2 
as a vaccine candidate, I went for its expression in various expression systems. 
ORF2 was expressed as a protein of ~80 kDa and ~72 kDa when cloned and 
expressed using pcDNA mammalian expression plasmid and can be seen using 
Western blot with anti-his antibodies (Fig. 12). The larger size or multiple forms may 
be associated with the glycosylation status of the protein.  
 
Figure 12: Expression of HEV ORF2 in mammalian cells. Lane 1 transfected with pcDNA, lane 2 
transfected with pcDNA-ORF2. 
2.3.2.2. Bacterial expression system 
The fragment of ~2 kb, encompassing complete ORF2 was cloned into the 
prokaryotic expression vector pET28a+ as described. After induction with IPTG, 
abundant amounts of the ORF2 was expressed (Fig. 13A, lane 2), as evidenced by 
their absence in uninduced cells (Fig. 13A lane 1) and by their reactivity on Western 
blots to the anti-His tag antibody (Fig. 13B). The protein accumulated as inclusion 
bodies, a feature exploited for further purification. The protein in washed inclusion 
bodies, after solubilization with urea, was purified by affinity chromatography on a 
nickel-agarose resin (Quiagen) (Fig. 13A lane 6-8). The purified protein of ~1mg was 
used for the production of antibodies (DAVID’s Biotech GmbH, Regensburg) in 
rabbit. The serum collected was able to detect the purified protein using ELISA at a 
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concentration of 1:80,000 according to the provider. I also checked the specificity of 
serum to HEV ORF2 through Western blot in various dilutions of serum. It was 
possible to detect the ORF2 even at a dilution of 1:30,000 (Fig. 15A&B). Detection 
was done using DAB (Sigma) detection system and ECL (Amersham).  
 
Figure 13: Expression and purification of His tagged HEV ORF2 in E. coli. A. The gel was 
stained with Coomassie blue. Lane 1 un-induced, lane 2 induced preload, lane 3 100 mM 
imidazole wash, lane 4 50 mM imidazole wash, lane 5 Eluent fraction 1, lane 6 eluent 3, lane 7 
eluent 6, lane 8 eluent 10, lane 9 beads, lane 10 protein marker. (B) Western blot analysis for E. 
coli expressed and purified HEV ORF2 protein. lane 1 un-induced , lane 2 induced , lane 3 
preload, lane 4 100 mM imidazole wash, lane 5 50 mM imidazole wash, lane 6 Eluent fraction 1, 
lane 7 eluent 3, lane 8 eluent 6, lane 9 elunet 8.  
2.3.2.3. Adenoviral expression system 
HEV ORF2 was expressed using adenoviral expression system to study its use as a 
vaccine candidate. The overall strategy for adenovirus construction is diagrammed in 
Fig. 8. HEV ORF2 was cloned into pAdTrack-CMV (Fig. 16), and the resultant 
construct is cleaved with a restriction endonuclease to linearize it and transformed 
into E. coli strain BJ5183 which has the supercoiled adenoviral vector pAdEasy-1. 
Recombinants were selected with kanamycin and screened by restriction digestion 
with PacI. Positive clones released a fragment of 4.5 kb (Fig. 14A) or 3.0 kb to 
expose its inverted terminal repeats. The resulting plasmid, pAd-GFP-F2, were 
subsequently transformed to Top10 E.coli cells (Invitrogen) for large-scale plasmid 
amplification followed by sequencing using gene specific primers in both forward and 
reverse directions. The plasmid was re-digested with PacI and transfected into a 
packaging cell line HEK 293 cells. After ~7 days, viruses were harvested by freeze 
thaw cycle and were used for infecting HEK 293 cells. Infection was carried out at an 
MOI of 10 and was monitored by tracking the GFP expression on cells (Fig. 14C and 
D). For checking the expression, RNA was isolated from the infected cells and used 
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for RT-PCR using gene specific primers (Fig. 14B). Expression in RNA level was 
seen in both 24 hpi and 48 hpi (Fig. 14B, lane 2 and 3), but not in the RNA control. 
To check the expression of ORF2 in protein level the infected cell lysate (48 hpi) was 
separted through SDS-PAGE, followed by a Western blot using anti-ORF2 antibody 
raised in rabbit. The HEV ORF2 was detected as a protein of MW ~88 kDa (Fig. 15B: 
lane 3), slightly above the E.coli expressed ORF2 band (Fig. 15B, lane 2).  
 
A 
 
HEV 
B
                1     2                         
       1        2         3         4        
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: A, lane 1, Agarose gel electrophoresis showing the positive clone of Ad-ORF2 after 
digesting with PacI. Lane 2, DNA marker. B, RT-PCR after infecting HEK293 cells with Ad 
viruses. Lane1 control, infected with Ad-GFP. Lane 2 and 3 with Ad-ORF2 at 24 and 48 hrs post 
infection respectively. Lane 4, positive control. C, GFP expression after infecting HEK 293 cells 
with Ad-GFP virus. D, infected with Ad-ORF2 virus. E and F, the respective phase contrast 
images. 
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Figure 15: Detection of HEV ORF2 by the antibodies raised in rabbit. A. E coli expression. Lane 
1, uninduced, lane 2, induced lane 3, purified HEV ORF2 protein. (B) Lane 1, Ad-GFP infected 
cell lysate. Lane 2, E. coli lysate expressing HEV ORF2 protein. Lane 3, Ad-ORF2 infected 
HEK293 cell lysate. 
 
Figure 16: Vector map of pAdTrack-CMV-ORF2 
2.3.3. Propagation of HEV: Cholesterol is required for the 
egress of HEV 
Membraneous compartments are used by viruses to cross membrane barriers during 
infection assembly and release. How viruses use these membrane lipid composition 
and protein-lipid binding for its biological functions is an area emerging area of 
investigation (Schroeder, 2010). Compared to other membrane lipids cholesterol has 
special features. They don’t form membrane of its own and penetrates less deeply in 
the hydrophobic layer of membrane. It is also one of the most diffusible lipid and 
analogous to small-molecule drugs in structure and function. Pathogenic process of 
viruses are interfered most effectively when they are concentrated into membrane 
rafts as cholesterol anchors on antiviral drugs and other inhibitors (Rajendran et al., 
2010). 
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Virus egression involves different pathways and most of these pathways are 
associated with lipid rafts (Noisakran et al., 2008; Yasuda et al., 2003). Cholesterol is 
associated with the egress of various viruses like sindbis virus (Hafer et al., 2009), 
bluetongue virus (Bhattacharya & Roy, 2008) and HIV (Zheng et al., 2003). A 
proposed model for HEV replication and egress is given in Fig. 5. Simvastatin is a 
member of the statin family of drugs that inhibit 3-hydroxy-3-methylglutaryl CoA 
reductase. Statins lower plasma cholesterol levels, resulting in reduction of the risk 
of cardiovascular disease. Simvastatin has been shown to suppress various viral 
infections including HIV, HCV etc (Delang et al., 2009; Giguere & Tremblay, 2004). 
Recently, an efficient cell culture system for HEV in PLC/PRF/5 and A549 cells using 
a genotype 3 HEV (strain JE03-1760F) was developed (Yamada et al., 2009). I used 
this system to study HEV propagation and to understand the role of cholesterol in its 
egress.  
 
As shown in Fig. 9, linearized construct pJE03-1760/wt was used to make infectious 
viral RNA. After transfection in PLC/PRF/5 cells the virus egress started at ~17 dpt 
as can be seen in Fig. 17 lane 4. The viral RNA level kept increasing and could be 
detected at 19 dpt. To check if the infection can persist up on splitting of the cells 
followed by media change PLC/PRF/5 now infected with HEV was trypsinized and 
splitted into different plates. HEV RNA was detected even up to 30 dps, Fig. 17, lane 
14. Up on treating with simvastatin, a drug which inhibits cholesterol synthesis, in 
PLC/PRF/5 cells infected with HEV (30dpt) there was considerable decrease in the 
amount of viral RNA. RNA level was decreased below half after egress, i.e. viral 
RNA in the media (0.45 and 0.53 fold change in case of 20 and 50 µM treated, 
respectively) and slightly less for cellular viral content (about 0.75 and 0.57 fold 
change in case of 20 and 50 µM treated, respectively) Fig. 18A and B. Untreated 
control samples were normalized. This shows that simvastatin has some effect in the 
egress of HEV and shows the possibility of using lipid rafts for its egress. 
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Figure 17: Propagation of HEV in cell culture. RT-PCR from the RNA isolated from PLC/PRF/5 
cells after transfection with HEV-RNA. Lane1, 2 dpt, (day post transfection), lane 2, 3 dpt, lane 
3, 7 dpt. Lane 4 17 dpt, lane 5 and 6 positive controls, lane 7, DNA ladder, lane 8, 19 dpt, lane 9, 
3 dps (days post splitting), lane 10, 5 dps, lane 11, 7 dps , lane 12 positive control, lane 13, 
DNA ladder, lane 14, 30 dps, lane14, 22 dps, lane 15, positive control, lane 16, DNA ladder. 
 
 
Figure 18: Effect of simvastatin on the HEV egress or replication. (A) Lane 1-3 RT-PCR of total 
RNA isolated from cells. Lane 1 contol, lane 2 treated with 20 µM simvastatin, lane 3, 50 µM of 
simvastatin, lane 4 -6, RT-PCR of RNA isolated from media, lane 4 control, lane 5 treated with 
20 µM of simvastatin, lane 6, 50 µm simvastatin, (B) Graphical representation of normalized 
fold change after quantification of the bands using image J. 
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2.4. Discussion 
2.4.1. Detection of HEV in swine 
Hepatitis E virus is widespread in many countries mainly in tropical and developing 
countries (Chandra et al., 2008). Here in the present study, out of 50 samples 
screened, 16 were found positive for HEV RNA presence which comes to about 
32%. The samples collected from different parts in Germany showed the diversified 
infection of domesticated swine. Detection of HEV RNA in the serum of 
domesticated pigs points to the view that HEV is a zoonotic disease and that 
domesticated pigs in Germany might be an important reservoir for the virus. Previous 
reports have shown the presence of HEV RNA in German wild boars (Schielke et al., 
2009) with about one third of the HEV cases in Germany may have been acquired in 
Germany. This is the first report of the presence of HEV RNA in domesticated pigs in 
Germany. Interestingly the closest related sequence is found to be swine HEV 
isolate from Japan of genotype 3 (accession no AB481226.1), after sequencing one 
of the PCR product and analyzing the sequence.  
 
HEV is introduced to new areas in the world due to the globalization of food markets 
in developed countries. It remains unclear if autochthonous HEV is imported from 
countries like China, Taiwan and the United States, which is having HEV genotype III 
and IV circulating or is from a wild reservoir. Here the evidence shows that HEV is 
zoonotic in countries where it is not endemic (Huang et al., 1992). 
 
In US and Taiwan zoonotic spread of HEV may be occurring as the human and 
swine HEV isolates belongs to same genotype very much related to each other and 
in these places HEV is not endemic (Huang et al., 2002; Li et al., 2000). There are 
reports about detection and sequencing of HEV in domestic pig livers sold in 
groceries in Japan and United States (Yazaki et al., 2003). HEV was also detected in 
raw pig livers from grocery shops in the Island of Hokkaido, Japan and these 
belonged to genotype 3 or 4. Liver specimens from 7 (1.9%) of 363 packages 
detected HEV RNA and had 99.5–100% sequence identity with a HEV infected 
patient in Hokkaido. Among 10 patients who had acute and fulmminent hepatitis 
during 2001-2002 in Hokkaido 9 had history of consuming under-cooked pig liver few 
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weeks before the disease onset. A study by Feagins et al shows that in US among 
127 pakckages of pig liver screened 14 were positive for HEV RNA, and belonged to 
genotype 3 of HEV. There are also reports (Matsubayashi et al., 2004; Mizuo et al., 
2005) confirming the the connection of domestic pigs in spreading of HEV to 
humans. Death of a 69-year old patient is reported due to fulminant hepatits during 
an HEV outbreak after eating barbecued pig liver/intestine (Mushahwar, 2008). In the 
same way, Mizuo et al. (Mizuo et al., 2005), also reported on 32 patients who 
consumed undercooked pig livers and/or intestines, 1– 2 months before the 
commencement of hepatitis E. All the above reports show that zoonotic foodborne 
transmission of HEV has a key role in the HEV epidemiology. This raises major 
health concerns and confirms that pigs form animal reservoirs for human HEV (Erker 
et al., 1999; Meng et al., 1998). There are also reports of people having acute 
autochthonous hepatitis E virus infection in Germany who didn’t had a history of 
travelling abroad (Brost et al., 2010) This shows the vulnerability of German 
population to Hepatits E virus and necessity of stringent screening of swine farms in 
Germany for the detection of HEV. It is also advisable that swine meat be properly 
cooked to sterilize it from the presence of virions. 
2.4.2. Cloning and expression of HEV ORF2 in various 
expression systems, ORF2 as a vaccine candidate 
HEV ORF2 protein which has the potential as a vaccine candidate has been studied 
for expression in various expression systems. An experimental vaccination study 
with cynomolgus monkeys tested a baculovirus-expressed ORF2 of MW 55000 
daltons, encompassing amino acids 112 to 609 of ORF2 from a Pakistani HEV 
isolate (Tsarev et al., 1994). This protein, synthesized in insect cells, was shown to 
be more efficient in generating antibody responses in experimentally infected 
monkeys (Tsarev et al., 1994) than fusion proteins made in E. coli. A chronological 
titration study shows that animals given from a dose of this 0.4-mg recombinant 
ORF2 protein protected them from hepatitis while challenging with high doses of the 
HEV. Primates were shown resistant to heterologous challenge with the Mexican 
strain of HEV after given a 50-mg dose of the recombinant protein (Tsarev et al., 
1997). In an independent experiment, recombinant baculovirus was engineered to 
contain 112–660 amino acids of the pORF2 that expressed as a stable and soluble 
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protein of MW 62,000 daltons. The 62 kDa protein was purified to near homogeneity 
and was used as an immunogen in experimental vaccination of cynomolgus 
monkeys (Aggarwal & Jameel, 2008). Protective immunity to HEV by using ORF2 
depends on the native confirmation mimicking the HEV proteins expressed during 
infection. As a result, different studies using various recombinant proteins show 
contradictory results. Immunization with a bacterially expressed peptide of MW 
23,000 daltons elicited a vigorous antibody response preventing experimental 
infection in two of three rhesus monkeys and reduced viral excretion in one (Im et al., 
2001). This protein form homodimers and thus mimics added tertiary structure of the 
capsid proteins. A vaccine candidate containing baculovirus expressed recombinant 
capsid protein showed protection in macaques infected with HEV. It passed a phase 
I clinical trial and was scheduled for phase II/III clinical trials (Robinson et al., 1998; 
Stevenson, 2000). Bacterially expressed peptide corresponding to aa 368–aa 606 of 
HEV ORF2 was used as a vaccine candidate (Li et al., 2005). When vaccinated 
twice with a 10 µg or a 20 µg formulation of this vaccine rhesus monkeys showed 
relatively high antibody response. The response to a 5 µg formulation was belated 
but reached comparable antibody levels. All the three vaccine formulations afford 
complete protection against infection with 104 genome equivalent dose of the 
homologous genotype 1 virus. At higher virus dose of 107, the same vaccine 
formulation partially protected against the infection and completely protected against 
hepatitis. This vaccine candidate had undergone phase 3 trial (Zhu et al., 2010). 
 
Adenovirus vectors offer several important advantages from a vaccine perspective. 
They have an exceptional safety record compared to live viral vaccines (Polo & 
Dubensky, 2002). Some of the promising reports pertaining to non-human primate 
models of the Ebola virus (Sullivan et al., 2000) Mycobacterium tuberculosis (Mtb) 
(Ronan et al., 2009) Papilloma virus (Berg et al., 2005) highlight the potential of Ad-
based vaccination approach. However, one concern against adenovirus for human 
use is the preexisting antibodies to adenoviruses which may compromise the efficacy 
of Ad-based vaccines. Works on Ad-based human immunodeficiency virus (Casimiro 
et al., 2003) and Ebola vaccines (Yang et al., 2003) has suggested that DNA priming 
followed by vector boosting can effectively overcome the effect of preceeding Ad 
immunity.  
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To investigate the utility of the Ad vector in developing HEV vaccines, I constructed a 
replication-defective recombinant Ad (rAd) vector by inserting the HEV ORF2 protein-
encoding gene into the early region 1 (E1) of the Ad genome. As the HEV ORF2 has 
been proposed as a vaccine candidate I looked for its expression in various 
expression systems with clear emphasis on adenovirus based expression system. Its 
expression was observed through RT-PCR and Western blot (WB). In WB, the size 
of ORF2 band was slightly higher than the band of ORF2 expressed in E.coli, which 
may be associated with post-translational modifications. Our main interest was to 
explore the utility of replication defective adenovirus type 5 (rAdV5) vectors as HEV 
vaccine carriers. The ORF2 protein, which is exposed on the surface of the virus, is 
the dominant virus antigen that interacts with host cell receptors (Kalia et al., 2009) 
and represents the major target of neutralizing antibodies (Acharya et al., 2003; 
Robinson et al., 1998; Srivastava et al., 2007).  
2.4.3. Cholesterol is required for the egress of HEV 
Lacks of a good infectious system have hindered the HEV research for instance in 
the search for antiviral drugs. The recent introduction of pJE03-1760 by (Yamada et 
al., 2009) provides many promises to take HEV research to the next phase. They 
used a faecal suspension with high load of HEV (2.0 x107 copies/ml genotype 3). 
This was used to develop an efficient cell-culture system for HEV in a 
hepatocarcinoma cell line (PLC/PRF/5). Serum samples containing IgM-HEV 
antibodies isolated from HEV infected patients of genotype 1, 3 or 4 neutralized the 
genotype 3 infectious virus demonstrating that HEV antibodies are broadly cross-
reactive. Serum samples obtained from patients 8.7 or 24.0 years after the 
commencement of HEV infection also prevented the propagation of HEV in 
PLC/PRF/5 cells, signifying the presence of lifelong HEV antibodies with neutralizing 
activity in individuals with past HEV infection. I was also able to establish an 
infectious system using this clone. PLC/PRF/5 cells transfected with HEV RNA were 
able to propagate the virus continuously as can be seen in Fig. 18A. I studied the 
egress of HEV in this system by depleting cholesterol in cells and by treating it with 
simvastatin.  
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Non-enveloped viruses entry and exit are mostly associated with lipid rafts (Briggs et 
al., 2003; Tsai, 2007). Lipid rafts are made of a mixture of glycosphingolipids and 
protein receptors structured in glycolipoprotein microdomains (Thomas et al., 2004). 
Signalling cycles at the plasma membrane involve reversible merging and 
disassembly of rafts driven by activation states of the raft proteins (Rajendran et al., 
2010) However, during virus morphogenesis, rafts merge irreversibly into microscale 
platforms of assembly and budding (Schmitt & Lamb, 2005; Schmitt et al., 2005; 
Waheed et al., 2008; Waheed & Freed, 2009; Waheed et al., 2009). Cholesterol-viral 
proteins characterized till now include that of HIV, influenza virus and Semliki Forest 
virus (Ahn et al., 2002; Nayak et al., 2004; Ono, ; Ono, ; 2010). They have key role in 
virus entry of egress. Glyco protein 41 associated with HIV fusion has cholesterol 
binding is considered to a cholesterol recognition consensus (CRAC) motif in a 
flexible domain of the ectodomain to introduce the trans-membrane segment 
(Vishwanathan et al., 2008). Viral fusion at the hemifusion stage and the ability of the 
isolated CRAC peptide to induce segregation of cholesterol in artificial membranes 
were effected due to mutation in this motif (Greenwood et al., 2008; Vishwanathan et 
al., 2008). Influenza A virus M2 protein is shown to co-purify with cholesterol 
(Schroeder et al., 2005). Its ability of proton translocation needed for virus uncoating 
is not depended on cholesterol. Its transmembrane channels are also too short for 
integral raft insertion (Schroeder et al., 2005). CRAC motifs in the flexible post-TM 
domain may be responsible for Cholesterol binding. This domain has three factors 
for binding to membrane rafts. Virualnce in mice is also associated with mutation of 
the CRAC motif. They have affinity to the raft–non-raft interface and can target M2 
protein to lipid rafts, the site for virus assembly (Chen et al., 2008). Cholesterol 
depletion slows down apical transport via sphingolipid-cholesterol rafts and causes 
mis-sorting of hemagglutinin (HA) to the basolateral membrane (Keller & Simons, 
1998; Simons et al., 1998). In a heterologous expression system it was observed 
that cholesterol is needed for the maturation and stability of M2. Ultrastructure of the 
Golgi was altered and interfered with cytotoxicity of expressed M2 during cholesterol 
depletion due to the cytotoxicity of expressed M2 (Cleverley et al., 1997). In alpha 
and flaviviruses the pH-dependent fusion of the viral and the endosomal membrane 
during virus infection is through class II fusion proteins, E1 and E (Heinz & Allison, 
2000; Kielian, 1995). The replication of Semliki Forest virus (SFV) can be restricted 
1000-fold In cholesterol-depleted insect cells (Phalen & Kielian, 1991), whereas a 
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less cholesterol-dependent point mutant, P226S, is only restricted 40-fold 
(Vashishtha et al., 1998).  
 
I hypothesize that HEV, a non-enveloped virus egress is associated with lipid rafts. 
Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the 
rate-limiting enzyme in cholesterol biosynthesis in the liver catalyzing the conversion 
of HMG-CoA to mevalonic acid (Bocan, 2002). Cholesterol depletion by 30 or 50 µM 
of simvastatin treatment drastically reduced the titer of HEV RNA in cell culture 
supernatant (Fig. 18B lane 4 - 6). Because the level of HEV RNA inside the cells 
remained largely unchanged (Fig. 18B, lane 1-3), simvastatin prevented the egress 
of viral particles. It is possible that cholesterol depletion through simvastatin leads to 
lipid raft disruption and thus affecting virus egress. Thus HEV may be using a 
pathway associated with lipids for its egress. It also points to the possiblility that 
cholesterol is associated with HEV egress and it may be binding to the viral particles. 
More studies are required to investigate this possibility. Other possibilities such as 
blocking the encapsidation, inactivation of particle assembly etc. can also be not 
ignored. Simvastatin (SIM) has been shown to exhibit a strong in vitro anti-HBV 
activity. Moreover, a combination of SIM with each of the individual nucleos(t)ide 
analogues lamivudine (LMV), adefovir (ADV), tenofovir (TEN) and entecavir (ETV), 
showed synergistic antiviral activity (Bader & Korba). Among the statins, simvastatin 
and mevastatin display the strongest in vitro anti-HCV activity, while fluvastatin and 
lovastatin have moderate inhibitory effects, and pravastatin is without an antiviral 
effect. Combinational therapy involving interferon-alpha (IFN-alpha) or HCV 
nonstructural (NS)5B polymerase or NS3 protease inhibitors and statins showed a 
good antiviral activity (Delang et al., 2009). Simvastatin produces vesicles using 
internal membranes which cannot sustain viral RNA synthesis and thus reducing 
infection through reduced transcription (Liu et al., 2006). Although this is a 
preliminary work as it was not repeated more than once due to technical problems, it 
shows that simvastatin treatment at this range depleted the cholesterol level. As a 
result, hepatitis E virus egress was hindered, but not much on its replication. This 
also makes simvastatin a promising drug candidate against HEV.  
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3. Chikungunya virus 
3.1. Introduction 
The reappearance of Chikungunya disease (Chik) caused by Chikungunya virus 
(ChikV) in the Indian Ocean Islands and India brought worldwide attention due to its 
explosive nature, high morbidity and complex clinicopathological manifestations. The 
disease caused by the ChikV is already involved in many outbreaks in Africa and 
Asia ever since its discovery in 1952 (Edelman et al., 2000; Powers & Logue, 2007). 
 
ChikV, an alphavirus belonging to the Togaviridae family, was first isolated from a 
febrile individual in Tanzania in 1952 (Bodenmann & Genton, 2006). Chikungunya 
means “that which bends up” from the Makonde root verb kungunyala, in reference 
to the stooped position developed due to the severe joint and muscle pain and other 
rheumatologic manifestations. Analysis of patients sera and the antigenic 
characterization collected during the outbreak found the agent to an alphavirus 
closely related to Mayaro and Semliki Forest virus and not dengue (Powers & Logue, 
2007). 
 
ChikV is transmitted to humans by several species of mosquitoes, with Aedes 
aegypti and Aedes. albopictus being the two main vectors. The symptoms of Chik 
normally start 4–7 days after the mosquito bite. Acute infection lasts 1–10 days and 
is characterized by a painful polyarthralgia, high fever, asthenia, headache, vomiting, 
rash, and myalgia (Pialoux et al., 2007). 
 
 
3.1.1.Geographic distribution of ChikV 
The latest outbreak of Chik fever which started in 2005 drawn in several countries in 
Africa, Asia and recently Europe. The first outbreaks were reported from Kenya and 
the Comoros. The south Western Indian Ocean region was hit seriously, including 
Mauritius, the Seychelles, Madagascar, Mayotte and La Reunion. In La Reunion, the 
most affected island, 266,000 cases were reported (34% of the population) along 
with 200 mortality cases associated with more severe form besides the classical 
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form of the disease. After reaching Indian subcontinent in October 2005 it caused 
more than 1.3 million cases (Bonn, 2006; Charrel et al., 2007; Pialoux et al., 2007). 
 
Sequencing of various ChikV isolates isolated from different geographical areas 
have shown the prevalence of three lineages with distinct genotypic and antigenic 
characteristics (Arankalle et al., 2007). Two genotypes are reported in Africa viz. 
West African and East Central South African (ECSA) genotypes. These two 
genotypes caused all the epidemics while the Asian genotype represented for whole 
of Asia (Powers & Logue, 2007). Introduction of ECSA genotype to the Asian 
continent for the first time was reported during the 2005-06 epidemic (Yergolkar et 
al., 2006). Chik cases were also reported recently from Europe, USA and Australia 
through travelers returning from affected areas (Bonilauri et al., 2008). The 
geographic distribution of ChikV showing its dispersal from Africa to otherparts of the 
world is shown in figure 1.  
 
 
 
Figure 1: Geographical distribution of ChikV showing dispersal pattern from Africa to 
the Indian Ocean and Europe during the past 20 to 50 years (de Lamballerie et al., 
2008). 
  
49 
Chapter 2  Introduction 
3.1.2. Molecular biology of ChikV 
Alphaviruses are enveloped positive stranded RNA viruses consisting of 
approximately 12,000 nucleotides (Fig. 2). The virus has its 5’ capped RNA with a 7-
methylguanosine while the 3' end is polyadenylated. 5' two-thirds of the genomic 
RNA forms the non-structural proteins translation site. From the Negative-stranded 
RNA intermediate a sub-genomic positive-strand RNA referred to as 26S RNA, is 
transcribed. Viral structural proteins are translated from this RNA (Strauss & Strauss, 
1988). ChikV has a genomic organization similar to other alphaviruses, consisting: 5' 
cap-nsP1-nsP2-nsP3-nsP4-(junction region)-C-E3-E2-6K-E1-poly(A) 3' (Khan et al., 
2002; Rice & Strauss, 1981; Strauss et al., 1984). 
 
Sequences in 5’ and 3’ regions of alphaviruses are highly conserved. It also possess 
conserved repeated sequence elements (RSEs) in the 3' non translated region (NTR) 
(Khan et al., 2002) 
 
 
 
 
Figure 2: Structure of the ChikV genome along with translational proteins  
 
3.1.3. Non-structural proteins 
The non-strucutural protein produces a big protein named P123. It is short-lived and 
accumulates during the early stage of infection. They are found localized along with 
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viral replication complex in endosomes and lysosomes. The viral genome replication 
to antigenome starts by its interaction with nsP4. This follows the P123 processing in 
which its cleaved into nsP1, nsP2 and nsP3. RNA polymerase complex membrane 
association is facilitated by this late processing. 
 
NsP1 is the viral RNA capping enzyme. This enzyme is important for the virus as all 
viral RNA synthesis and replication takes palce in the cytoplasm, and host encoded 
methyl transferase is restricted to the nucleus. 
 
Eukaryotic capping enzymes form covalent binding with GMP, where as for NSP1 it’s 
a covalent link between 7-methyl-GMP and nsP1. This capping is associated through 
various steps, 1. methylation of GTP takes place and thus forms m7GMp-nsP1 
complex. 2. This 7-methyl-GMP complex is transferred from NSP1 to the mRNA to 
create the cap structure. NSP1 is palmiyolated and is also associated with host cell 
cytoskeleton remodeling. This process induces filopodium-like structural 
arrangement at the surface of the host cell. 
 
The second non-structural protein NSP2 has two different domains having separate 
functional activities. The N-terminal region forms RNA polymerase complex and 
encodes trisphosphatase and RNA helicase activity. The second domain of the 
protein in C-terminal encodes a protease which specifically cleaves the P123 to 
release other four proteins.  
 
The third protein NSP3 functions are not well defined but are thought to be related to 
negative strand and sub genomic 26S mRNA synthesis.  
 
The fourth protein NSP4 encodes an RNA dependent RNA polymerase (RdRp). The 
synthesis of genomic and sub genomic RNA takes place through the recognition of 
replication specific signals. A 26S sub genomic mRNA trnanscription is also 
associated with NSP4 were initiation of RNA synthesis takes place internally on sub 
genomic RNA. The structural proteins of ChikV are translated from this (Ahola et al., 
1997; Froshauer et al., 1988; Hardy & Strauss, 1989; Khan et al., 2002; Laakkonen 
et al., 1998; Lemm et al., 1994; Malet et al., 2009; Strauss & Strauss, 1994). 
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3.1.4.Structural proteins 
The structural poly-proteins are associated with the virus structure. The viral capsid 
protein (VCP) has autocatalytic protease activity which results in the cleavage from 
rest of the structural protein. After the self-cleavage, the VCP interacts with 
ribosomes followed by viral RNA binding and assembly into icosahedric core 
particles. This nucleocapsid protein (NCP) then interacts with the cytoplasmic 
domain of envelope protein 2 (E2) at the cell membrane, and thus results in budding 
and formation of mature virions. These new virions attach to cell surface through an 
uncharacterized cell receptor using endocytosis. The membrane proteins fuse with 
cell membrane during the process. This eventually results in the release of NCP to 
cytoplasm, followed by ribosome binding leads to uncoating of the genomic RNA to 
become accessible. Ribosome also binds with E3 protein while its function is 
unknown. 
 
The envelope protein 2 (E2) is a by products of structural protein p62. The 
processing of p62 takes place through cellular protease furin which eventually 
releases the E2. Processing p62 precursor takes place in the end mostly to avoid E1 
fusion activation before its final export to cell surface. Structural protein processing 
by furin produces E2-E1 heterodimer. This E2-E1 heterodimer is unstable and 
dissociates at low pH while, p62-E1 heterodimer is stable. The E2 protein contain 
transitory transmembrane region which is disrupted by palmitoylation. This takes 
place in the C terminal region. This palmitoylation results in re-arrangement of the 
protein from the luminal to the cytoplasmic side. This is essential as it forms 
important structure for the virus budding by interacting with CP. The release of E2 C-
terminus takes place as a later part of protein export in cytoplasm. The E2 gets 
attached to the cells by binding to unknown cellular receptor.  
 
The small structural protein 6K is a membrane protein and is associated with virus 
glycoprotein processing. It is also found to be important for membrane 
permeabilization, and the budding of viral particles. Due to this lipophilic properties, 
the selection of lipids that interact with the transmembrane domains of the 
glycoproteins is proposed to be mediated by the 6K protein. This also affects the 
deformability of the membrane which is important for the budding process. 
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Envelope protein 1 (E1) is a class II viral fusion protein. This fusion activity is 
inhibited while E1 is bound to E2 in mature virion. The dissociation of E1/E2 
heterodimer and associated trimerization of the E1 subunits occurs during the 
acidification of endosomes, a process which occurs after the virus attachment to the 
target cell and endocytosis. The E1 trimer activates the release of viral nucleocapsid 
to cytoplasm during the cell and viral membrane fusion. This fusion is activated 
during the presence of cholesterol and sphingolipid. (Choi et al., 1996; DeTulleo & 
Kirchhausen, 1998; Khan et al., 2002; Sanz et al., 2003; Smit et al., 1999; Strauss & 
Strauss, 1994). 
3.1.5. Sequence requirements for the activity of alphavirus 
capsid protease 
The alphaviral single-stranded RNA genome is packaged into a nucleocapsid made 
up of 240 copies of the basic capsid protein (Cheng et al., 1995). The nucleocapsid 
is surrounded by a lipid bilayer containing two integral glycosylated membrane 
proteins (E2 and E1) and a small peripheral protein E3. The alphavirus capsid is 
multifunctional and plays a key role in the viral life cycle. The capsid is made up of 
two domains, the unstructured, RNA binding N-terminal segment (residues 1–118) 
and a C-terminal globular protease domain (residues 119-267); (Choi et al., 1996). 
The serine protease domain consists of a β-barrel motif with a typical serine-
histidine-aspartic acid catalytic triad with the active site interspersed between two 
subdomains (Choi et al., 1997; Owen & Kuhn, 1997). 
 
The first cleavage event in SFV is executed by the serine protease domain of the 
capsid protein. Cleavage occurs between tryptophan 267 and serine 268 of the 
polyprotein and releases the capsid protein. After the autoproteolytic cleavage, the 
free carboxylic group of W267 interacts with the catalytic triad (H145, D167 and 
S219) and thus leads to self inactivation. Even though the capsid protease is a 
chymotrypsin like protease, there is an important structural difference to this 
protease family. The viral protease lacks the C-terminal α-helix present in 
chymotrypsin and instead forms two short β-strands. These β-strands lead to 
bending of the C-terminus towards the centre of the capsid protein that allows the 
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last W267 side-chain to reach the active site for auto-cleavage to occur (Choi et al., 
1997). 
3.1.6. Nuclear Import and export of ChikV capsid protein 
The bi-directional transport of molecules between nucleoplasm and cytoplasm 
occurs through the nuclear pore complex (NPC), a supra molecular structure of the 
nuclear envelope (NE) (Vasu & Forbes, 2001). Nuclear pore complexes allow 
passive diffusion of ions and small proteins up to size of 40 kDa or less than 9 nm in 
diameter, but restrict passage of larger molecules to those containing an appropriate 
targeting signal (Paine et al., 1975). Nucleocytoplasmic transport is a tremendous 
activity that is mediated by the interaction of transport cargoes with karyopherins. 
Karyopherins are adaptor proteins that recognize cargo proteins containing a nuclear 
localization signal (NLS) and which also interact with the transport receptor importin 
β. Together, these proteins build up a ternary complex that interacts with the nuclear 
pore complex and translocates into the nucleus (Lange et al., 2007). The NLS used 
by the classical nuclear import pathway is a short stretch of positively charged amino 
acids (aa), arginines and lysines that lack strict consensus sequence (Dingwall & 
Laskey, 1991). A monopartite NLS, like that of SV40 large T antigen, is composed of 
a cluster of five to seven basic amino acids and a typical bipartite NLS contains two 
clusters of basic amino acids separated by a linker of 10–11 amino acids (Dingwall 
et al., 1982; Kalderon et al., 1984; Lanford & Butel, 1984). 
 
Contrariwise, nuclear export signals (NES) are recognized by exportins and allow 
proteins to be transported actively from the nucleus to the cytoplasm through the 
NPC (Turner & Sullivan, 2008). NES are specifically bound by exportin known as 
exportin 1 (XPO1 or CRM1). This transport is mediated via binding to the GTP-
bound form of the guanine nucleotide-binding protein Ran (RanGTP). The most 
commonly identified NES are short leucine-rich signals, although other hydrophobic 
residues, such as isoleucine, methionine, phenylalanine and valine, can contribute to 
the signal (Nigg, 1997).  
 
Alphaviruses of the togaviridae family contain capsid protein localized both in the 
cytoplasm and nucleus (Atasheva et al., ; 2010; Favre et al., 1994). Chikungunya 
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virus(ChikV) capsid protein (CP) is of particular importance due to the explosive 
nature, high morbidity and complex clinicopathological manifestations of ChikV 
disease (Pialoux et al., 2007). The disease caused by ChikV has already been 
involved in many outbreaks in Africa and Asia since its discovery in 1952 (Edelman 
et al., 2000; Powers & Logue, 2007). ChikV capsid protein exhibits many functions. It 
selectively packages the viral genome, but not cellular or viral subgenomic RNA into 
viral particles, and encodes protease activity required for processing of the structural 
polyprotein (Thomas et al., 2010). 
 
Alphaviruses of the family togaviridae contain an icosahedral nucelocapsid which is 
localized both in cytoplasm and nucleus (Atasheva et al., ; Favre et al., 1994). The 
ChikV capsid is of particular importance, due to the explosive nature, high morbidity 
and complex clinicopathological manifestations of ChikV disease (Pialoux et al., 
2007). The disease, caused by the ChikV has already been involved in many 
outbreaks in Africa and Asia ever since its discovery in 1952 (Edelman et al., 2000; 
Powers & Logue, 2007). ChikV capsid protein exhibits many functions. It selectively 
packages the viral genome, but not cellular or viral subgenomic RNA into viral 
particles. Capsid protein also encodes protease activity required for processing of 
the structural polyprotein. 
 
As nuclear and cytoplasmic trafficking may play an important role in the regulation of 
ChikV function, I have sought to further define the nuclear localization and nuclear 
export signals in ChikV capsid. Here, I demonstrate that ChikV capsid binds to 
karyopherin α (kar α) for its nuclear translocation and that the C-terminal NLS 
domain is enough for this interaction. I am also showing that ChikV capsid encodes a 
CRM1 mediated nuclear export signal which is mapped to a leucine rich region. 
Deletion of 90 aa from N-terminal region of ChikV capsid made the protein purely 
nuclear, which shows that this region is important for its cytoplasmic localization or 
export. 
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3.2. Materials and Methods 
3.2.1. Materials 
Materials and devices if not mentioned here are written in chapter 1. 
3.2.1.1. Devices 
Confocal microscope Leica Confocal Microscope, Wetzlar,  
3.2.1.2. General material 
Coverslips 12 mm (round), 18 mm x 18 
mm (square) 
Gerhard Menzel GmbH, Braunschweig 
Microscope slides (26 mm x 76 mm x 1 
mm) 
Engelbrecht, Edermünde 
3.2.1.3. Chemicals 
DRAQ5 Cell Signaling Technology, Danvers, USA 
Leptomycin B Sigma Aldrich, St. Louis, USA 
Mounting medium Dako, Carpinteria, USA 
3.2.1.4. Antibodies 
Anti-FLAG (Mouse) Sigma Aldrich, St. Louis, USA 
Anti-GFP (Rabbit)  Acris antibodies, Herford 
3.2.1.5. Vectors 
pSMART LCKan Kind gift of Christian Drosten, Universität 
Bonn 
pChikcap  
pCAGGS α 1, 2, 3, and 4 
Produced in lab, GenBank: HM369441.1 
Kind gift of P. Palese, Mount Sinai 
School of Medicine, New York. 
pCR 2.1 TA cloning vector Invitrogen, Karlsruhe 
pET28a Novagen, Merck Chemicals Ltd, 
Nottingham, UK 
pEGFP-N1 Clonetech, Mountain view, USA 
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3.2.2. Isolation of ChikV RNA from patient serum 
Chikungunya viral RNA was isolated from serum of patients who travelled to the 
Indian Ocean during the 2007 outbreak, using Roche high pure viral RNA kit 
according to the manufacturer’s instruction. RNA was reverse transcribed and 
amplified using the primers chik_cap_fwd 5’-atggagttcatcccaacccaaac-3’ and 
chik_cap_rev 5’-tccactcttcggctccctcag-3’. The PCR product was cloned to pCR 2.1 
TA cloning vector (Invitrogen) according to manufacturer’s instruction and positive 
clones were screened using restriction digestion. They were further sequenced at 
both forward and reverse direction. The final ChikV capsid sequence was submitted 
to NCBI genebank (GenBank: HM369441.1). 
3.2.3. Alphavirus capsid protease: sequence requirements 
for the capsid protease activity 
3.2.3.1. Cloning and mutagenesis 
ChikV capsid protein (1 to 261) was cloned as fusion protein with FLAG tag 
(DYKDDDDK) at the N-terminus and GFP tag at the C-terminus in pEGFP-N1 vector 
(Clontech) using primers Flagchik cap_fwd and ChikcapXmaI_WT_rev (table 1). The 
PCR products were cloned between the HindIII and XmaI sites of the vector pEGFP-
NI. All clones were verified by sequencing in both forward and reverse direction. 
Deletion mutant ∆46, was constructed using primers FlagChik cap_fwd and 
Chikcap∆46_rev (table 1). Other mutations were incorporated by adding mutations in 
the reverse primer in the C-terminal of the protein (see table 1, no 4-10). As template 
for PCR, plasmid pSMART LCKan containing ChikV structural genes (Kowalzik et 
al., 2008) or pChikcap (GenBank: HM369441.1) containing the ChikV capsid gene 
was used. 
 
Serine 213 in the catalytic triad was mutated to alanine by fusion PCR (Szewczyk et 
al., 2006) using primers [5’-atggactacaaagacgatgacgataagatggagttcatcccaac-3’, 5’-
aagatcggtctaccggcgtcccctggttt-3’] and [5’-aaaccaggggacgccggtagaccgatctt, 
atcccgggtccactcttcggctc-3’]. Error-prone PCR was performed using oligos FlagChik 
cap and ChikcapXmaI_WT (table 1) as primers. Reaction mixtures contained 10x 
PCR buffer (Qiagen), 5 mM Mg2+, 10 ng of template DNA, 10pM of each primer, and 
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2.5 U of Taq polymerase. The reaction conditions were as follows: step 1, 5 min, 95 
ºC ; step 2, 30 s, 94 ºC ; step 3, 30 s, 58 ºC ; step 4, 45 s, 72 ºC ; and step 5, 7 min, 
72 ºC ; steps 2 to 4 were repeated 35 times.  
 
Table 1: Primers used to mutate the capsid protease of Chikungunya virus. 
 
Mutation 
 
Primer 
 
Nucleotide sequence (5’-3’) 
 
  
Wt Flagchik cap_fwd aagcttatggactacaaagacgatgacgataagaccatggagtt
catccc
EGAEEW (wt) ChikcapXmaI_WT_rev atcccgggtccactcttcggctc 
∆46 AA 
(deletes aa 216-261) 
Chikcap∆46_rev atcccgggttctaccgctgtcccc 
W261A (EGAEEA) ChikcapW-A_rev atcccgggtcgcctcttcggccc (4) 
A258E (EGEEEW) ChikcapA-E_rev atcccgggtccactcttcttccccctcgg (5) 
A258S (EGSEEW) Chikcap3A-Sr_rev atcccgggtccactcttcggacccctcgg (6) 
E256A (AGAEEW) Chikcap_E-A_rev atcccgggtccactcttcggccccggc (7) 
A258T (EGTEEW) ChikcapA-Tr_rev atcccgggtccactcttcggtcccctcgg (8) 
E260D (EGAEDW) Chikcap_E-D_rev atcccgggtccaatcttcggccc (9)                         
E260A (EGAEAW) Chik_cap_E-A_rev  atcccgggtccacgcttcggccc (10) 
 
3.2.3.2. Cell culture and transfection 
HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, and 100 μg/ml 
streptomycin. For transfection, HEK293 cells were seeded in 12-well plates at a 
density of 2x105 cells and transfection was performed using turbofect (Fermentas) 
transfection reagent according to the manufacturer’s instruction 
3.2.3.3. Western blot  
48 hours post transfection cells were washed once with PBS followed by lysis, using 
RIPA buffer (Sigma). Protein samples were subjected to 12% SDS-PAGE and 
transferred to PVDF membrane (Amersham) by using the Xcell II blot module 
(Invitrogen) and blocked overnight at 4 ºC with 3% BSA in PBST. The membranes 
were probed with monoclonal anti-FLAG antibodies (Sigma) followed by anti-mouse 
secondary antibodies conjugated with horseradish peroxidase (Santacruz). Blots 
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were visualised with the enhanced chemiluminescence (ECL) detection reagents 
(Amersham, UK). 
3.2.3.4. Protein modelling and analysis 
The structure of the capsid protease was modeled using automated homology 
modelling server 3D-JIGSAW (http://bmm.cancerresearchuk.org/~3djigsaw/) (Offman 
et al., 2008). The template, Semliki Forest virus capsid protein (PDB ID 1vcp_C) is 
91% identical in sequence to the ChikV capsid protease domain, which makes the 
model more reliable. Comparison of WT and mutant structures were done using 
SPDBV software (Guex & Peitsch, 1997). The figures were generated using pymol 
(http://www.pymol.org). Energy computations were done with the GROMOS90 
implementation of Swiss-PdbViewer in collaboration with Dr. Jagdish Rai, Beckman 
Institute, Illinois, USA. 
3.2.4. Nuclear Import and export of ChikV capsid protein 
3.2.4.1. Cloning and mutagenesis 
ChikV capsid full-length and mutants were cloned between HindIII and XmaI sites of 
the multiple cloning site of pEGFP-N1 vector using primers, HindIIIChikcap_fwd and 
Chik capXma1_rev ( table1, no1 and 2). Expression vector pet28a (Invitrogen) was 
used to clone ChikV capsid sequence amplified by PCR using primers 
chk_petcapsid_fwd (5'-ggatccatggagttcatcccaacc-3', chk_petcapsid_re 5'-
ctcgagtccactcttcggctc-3') from pChikcap (GenBank: HM369441.1) containing ChikV 
capsid gene as template or using ChikkcapSDM_S-A between BamH1 and Xho1 
sites.  
 
Deletion mutants were constructed using the primers given in table 1. Construction 
of Chikcap ∆46 has been described previously. To mutate leucine at position 149 
and 152 to alanine, an overlap PCR was performed using primers 5’-
aagcttatggagttcatcccaacccaaac-3”, 5’-cttaaaggccgctttggccgcgtccgc-3’ and 5’-
gcggacgcggccaaagcggcctttaag-3', 5’-atcccgggtccactcttcggctc-3' both the fragments 
were having 27 nucleotides complementary in the overlapping region. Mammalian 
expression vector pCAGGS containing karyopherin α 1, 2, 3 and 4 with an N-
terminal FLAG tag were the generous gift of Dr. P. Palese, and has been described 
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previously (Shaw et al., 2005; Wang et al., 1997). Deletion mutant pCAGGS ∆ 259 
karyopherin 4 was constructed by digesting the full-length vector with Tth111I 
followed by ligation. 
 
Table 2: Primers used for the the FL or deletion constructs 
 
Protein 
 
Primer 
 
Nucleotide sequence (5’-3’) 
  
Full-length HindIIIChikcap_f      aagcttatggagttcatcccaacccaaac 
    " ChikcapXmaI_WT_rev atcccgggtccactcttcggctc-3’   
∆118 aa  
from C-terminal 
Chikcap143_rev atcccgggtcccctttacgtgtgctgg 
3.2.4.2. Protein expression and purification 
N-terminal His tagged pet28aChik cap was transformed to Bl21 cells (Invitrogen) and 
the protein was expressed in 500 ml culture containing kanamycin. The bacterial 
culture was grown at 37 °C until OD600 had reached 0.6, induced with IPTG at a 
concentration of 1 mM and kept overnight at 21 ºC in a rotary shaker. The cells were 
pelleted and resuspended in 6 ml of buffer containing PBS and 5% glycerol, and 
lysed by sonication for 3 min. The cell lysate was spun at 5,000 rpm for 20 min and 
imidazole was added to the supernatant at a concentration of 10 mM. Precharged 
and prewashed NiNTA beads (Invitrogen) of 0.6 ml of bed volume was mixed with 
the lysate at 4 °C for 1 h. It was then loaded to column and washed with 50 ml of 
PBS containing 20 mM imidazole and 5% glycerol. Protein was eluted using elution 
buffer containing PBS, 5% glycerol and 300 mM imidazole. The eluents were 
dialyzed against buffer containing PBS and 5% glycerol. Eluents were analysed on 
SDS-PAGE and confirmed by Western blot using anti-His antibodies. Protein 
estimation was done using the BCA kit.  
3.2.4.3. Pull-down assay  
Pull-down assay was performed as described before (Haenni et al., 2008). Purified 
His-tagged ChikV capsid protein was incubated with whole cell extracts from 
HEK293 cells; either untransfected or transfected with FLAG tagged karyopherinα 1-
4, ∆ 259 karyopherin 4. Ni-NTA beads of 10 µl resuspended volume were added to 
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this protein lysate mix and incubated further at 4 ºC. Samples were centrifuged and 
the supernatant was discarded. The beads were washed further using RIPA buffer 
and finally 40 μL of Laemmli buffer was added to the beads and boiled for 10 min. 
The samples were subjected to SDS–PAGE and transferred to nitrocellulose 
membrane. The membranes were probed with monoclonal anti-FLAG antibodies 
(Sigma) followed by anti-mouse secondary antibodies conjugated with horseradish 
peroxidase (Santacruz). Blots were visualized with the enhanced 
chemiluminescence (ECL) detection reagents (Amersham, UK). 
3.2.4.4. Co-imunoprecipitiation 
For Co-IPs, HEK293 grown in Petri dishes (10 cm) were transfected with FLAG 
karyopherin α-4 and pEGFP-ChikcapFL, using Turbofect (Fermentas) transfection 
reagent. Cell lysates were prepared 48 h after transfection in 1.5 ml of RIPA lysis 
buffer. Aliquots which contain about 500 µg of total protein were incubated with 1 µg 
of anti-FLAG mouse monoclonal antibody (Sigma) or a non-specific monoclonal 
antibody for 1 h at 4 ºC. A 50% suspension of protein A–Sepharose (Sigma), 
blocked by incubation with 1% BSA in PBS, was added to the lysate and incubated 
for 2 h at 4 ºC with shaking. The beads were collected by centrifugation, followed by 
three washes with RIPA lysis buffer. After the final wash, the supernatant was 
discarded, 20 μL of Laemmli buffer was added to the beads and boiled for 10 min. 
The samples were subjected to SDS–PAGE and analyzed by Western blotting using 
anti-GFP antibody. 
3.2.4.5. Cell culture and transient transfections, treatment with LMB 
and immunofluorescence 
HEK293 cells were maintained in DMEM supplemented with 10% FCS, 100 U/ml 
penicillin and 100 μg/ml streptomycin. For transfection, HEK293 cells were seeded in 
12-well plates at a density of 2 × 105 cells and transfection was performed using 
Turbofect (Fermentas) transfection reagent according to the manufacturer’s 
instructions. For the experiments with Leptomycin B (LMB), cells were treated with a 
final concentration of 20 ng/ml LMB, for 4–16 h. For detection of overexpressed 
proteins by immunofluorescence, HEK293 cells were fixed for 10 min in a solution 
containing 4% formaldehyde in PBS. Cell were washed twice in PBS for five min and 
incubated with 5 µM DRAQ5 (Cell Signaling Technology) according to 
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manufacturer’s instruction. Finally, coverslips were mounted on slides with anti-fade 
mounting media (Dako). Samples were analyzed on a Leica confocal microscope. 
3.2.4.6. Nuclear localization analysis 
NIH Image J v1.30 software was used to quantify the nuclear localization of GFP 
fusion proteins. All confocal images were quantified using settings where the 
intensity of GFP fluorescence was linear and ranged from 10 to 160 pixel values 
(Sheng et al., 2004). To examine the nuclear localization of GFP fusion proteins, a 
square with an area of 225 pixels was used to measure the mean intensities of three 
different regions in the nucleus and the cytoplasm of a representative cell from each 
of 3 transfections. Thus, 3 representative cells yielded a total of 9 areas from the 
nucleus and 9 areas from the cytoplasm. Relative nuclear localization is reported as 
the ratio of the mean intensity of GFP fluorescence in the nucleus and cytoplasm 
(nuclear/cytoplasmic ratio, N/C ratio). 
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3.3. Results 
3.3.1. Alphavirus capsid protease: sequence requirements 
for the activity 
Alphaviral replication depends on the efficient and precise cleavage after tryptophan 
261 executed by the capsid protease. (Melancon & Garoff, 1987) This tryptophan site 
is conserved in all alphaviruses analyzed including ChikV (Fig. 3A). In order to 
determine sequence requirements of the ChikV capsid protease I cloned the ChikV 
capsid in fusion with GFP. Figure 3B shows that the ChikV capsid protease efficiently 
cleaved the capsid from the GFP tag, which also shows that S262 is not important for 
the cleavage. A mutation of S213 to alanine inactivated the protease and thus 
prevented cleavage of GFP from the capsid protease Fig. 3B, lane 8. Since S213 is 
an essential part of the autocatalytic triad, this cleavage was executed by the protease 
domain of the ChikV capsid protease. Thus, the capsid protease activity monitored in 
the assay depended on the integrity of the catalytic triad of the protease.  
 
I next analyzed if a deletion at the C-terminus retained its protease activity. As shown 
in Figure 3B, lane 2, a deletion of 46 aa from the C-terminus completely abolished the 
protease activity. While E256, G257 and E259 in ChikV capsid are conserved among 
alphavirus capsid, the aa in positions 258 and 260 seem to vary specifically between 
virus species (Fig. 3A). Thus, I set out to analyze the influence of the C-terminal aa 
sequence for the activity of the ChikV capsid protease. As expected, mutating 
tryptophan in the 261 position to alanine (W261A) completely inactivated the protease 
(Fig. 3B, lane 9). I then analysed whether amino acids near tryptophan in the 
cleavage site of the protease domain will have any effect on enzyme activity. As 
shown in the Western blot (Fig. 3B, lanes 3-6 and 10 to 11), mutations at these sites 
were not found to have any effect on the protease activity. Even the substitution of 
E256 conserved in all alphaviruses to alanine did not have any effect on the activity of 
the capsid protease.  
 
To identify additional motifs important for the protease activity, I performed an error-
prone PCR to introduce mutants. I obtained and analyzed mutants with substitutions 
of P61L, Q86R, A207V, or I227K. Mutants P61L, Q86R, and A207V of the capsid did 
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not have any effect on the activity of the protease (data not shown). However, an 
exchange of isoleucine 227 to lysine completely inactivated the protease activity (Fig. 
3B, lane 7). 
 
To our knowledge the importance of I227 for the activity of alphaviral capsid 
proteases has not been reported before. Thus, I further analyzed the loss of activity 
by molecular modelling and comparison of WT and mutant structures. Figure 4 
indicates that the lysine introduced at position 227 is spatially very close to the 
catalytic triad and may disrupt electrostatic interactions in the catalytic site. Rotamers 
of lysine 227 can make a salt-salt bridge with aspartic acid 161. This rotamer is a 
preferred conformation of lysine 227 considering the electrostatic interaction with 
surrounding residues and the absence of steric hindrances (Fig. 4B). The 3.38 Å 
distance between the side chain nitrogen atom NZ of lysine 227 and the side chain 
oxygen atom OD1 of ASP 161 is the ideal length of a salt bridge which is less than 4 
Å. This distance between OD1 and NZ is almost the same before (3.38 Å) and after 
energy minimization (3.49 Å). Here PDB nomenclature is used in denoting the side 
chain atoms of amino acids. NZ is the nitrogen atom of amino group of side chain of 
lysine. The OD1 is one of the oxygen atom of carboxyl group of side chain of aspartic 
acid. 
 
Figure 3A: Conserved amino acids near the cleavage site between tryptophan and serine at the 
C-terminus of the capsid protein of alphaviruses. The arrow indicates the cleavage site. Figure 
3B: Mutations affecting the protease activity of the ChikV capsid protease. Capsid-GFP fusion 
constructs were transfected into HEK293 cells. 
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Figure 4: Molecular modelling of the catalytic triad of ChikV capsid protease. Capsid protease 
was modeled using automated homology modelling server 3D-JIGSAW using Semliki Forest 
virus capsid protein as template. A) Wt catalytic triad in native enzyme with isoleucine at 227. B) 
The catalytic triad in mutant enzyme with lysine at 227. The side chain of lysine 227 is very 
close to side chains of the catalytic triad that will disrupt the electrostatic interactions of 
catalytic triad. The distance between OD1 of aspartic acid 161 and NZ of lysine 227 is 3.38 Å 
which is the optimal distance to form a salt bridge between these residues.  
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3.3.2. Nuclear Import and export of ChikV capsid protein 
3.3.2.1. The ChikV capsid has preferential binding to karyopherin α 3 
and karyopherin α 4 
 
Several karyopherins are known to directly interact with different cargo proteins in the 
cytoplasm and to carry the cargos through nuclear pores into the nucleus. To 
decipher the mechanisms of ChikV capsid nuclear translocation, I analyzed the 
interactions of ChikV capsid with various karyopherins. ChikV capsid protein was 
expressed in E.coli with His tag and purified using the Ni-NTA column (Fig. 5A).  
Authenticity of the protein was confirmed through Western blot using anti-His tag 
antibody (Fig. 5B). Purified ChikV capsid was incubated with HEK293 cell lysate; 
transiently transfected with various FLAG tagged Karyopherins (kar α 1-4). It was 
found that ChikV capsid interacts with the karyopherin α 4 specifically and weakly with 
karyopherin α3 (Fig. 6A: lane 3and4).  
A B 
 
Figure 5: His tagged purification profile of ChikV capsid protein. ChikV capsid expressed in E. 
coli in native form was purified using Ni-NTA column. A shows the coomassie stained SDS-
PAGE of His tagged ~37 kDa purified protein (~20 ng/µl). B shows the Western blot of the 
protein with ∝His antibody. Arrows indicate the protein position. 
 
To confirm the interaction, I investigated the interaction between ChikV capsid and kar 
α 4 in mammalian cell line. HEK293 cells were transiently transfected with FLAG-kar 
α 4 and ChikV-cap-GFP. The protein complex was co-immunoprecipitated with an 
anti-FLAG antibody bound to protein A–Sepharose. The bound proteins were 
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subjected to SDS-PAGE followed by Western blot using anti-GFP antibody. As shown 
in Fig. 6B (lane 2), ChikV capsid co-immunoprecipitated with kar α 4. No binding was 
observed in the control experiments using only beads or by using a non-specific 
antibody. 
 
 
 
 
Figure 6: ChikV capsid protein interacts with karyopherins. A) Pull-down assay with E. coli 
expressed, purified ChikV capsid was performed. Lane 1-4 with karyopherin α 1, 2, 3 & 4. 
Karyopherins bound to capsid was detected with anti-FLAG antibody B) Immunoprecipitation to 
confirm the interaction of karyopherin α 4 with ChikV capsid. Lane 1, beads, lane 2 with anti-
GFP antibody, lane 3, non-specific antibody, lane 4 Input. 
3.3.2.2. NLS major binding site is adequate for the interaction 
between kar α 4 and capsid 
Karyopherin α molecule contains two NLS-binding sites that directly recognize NLS 
sequences of cargo proteins. The primary NLS binding site is located at the N-
terminal armadillo (alpha helices that form a hairpin structure); (arm) repeats 2–4, 
while the secondary NLS binding site is located at the C-terminal arm repeats 7–9 
(Fig. 7A). NLS major binding site is associated in interaction with monopartite NLS, 
while minor binding site associated with bipartite NLS. (Conti et al., 1998; Fagerlund 
et al., 2005; Fontes et al., 2000; Melen et al., 2003).  
 
To further characterize the mechanism of ChikV capsid binding to kar α 4 molecule, I 
created deletion mutant karα-4∆ 259, which lacks the minor binding site. I checked if 
the minor binding site is required for the interaction with ChikV capsid through pull- 
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down assay. Karα-4∆ 259, which lacks the minor binding site was able to interact with 
ChikV capsid alone (Fig. 7A lane 4) or in the presence of excess kar α 4-FL (Fig. 7B, 
lane 5). This shows that the N-terminal arm repeats of kar α 4 form the binding site for 
ChikV capsid. 
 
 
 
Figure 7A: Molecular model of karyopherin α 4. The major and minor NLS binding sites are 
marked. Fig. 7B: NLS major binding site is adequate for the interaction between kar α 4 and 
capsid: Lane 1 input of kar α 4-FL. Lane 2, input of kar α 4∆ 259. Lane 3 pull-down assay with 
kar α 4-FL. Lane 4 pull-down assay with kar α-4∆ 259. Lane 5 pull-down assay with mix of both 
kar α 4-FL and kar α-4∆ 259. Lane 6 input of kar α 4-FL and kar α-4∆ 259 mix. 
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3.3.2.3. ChikV capsid encodes a CRM1-dependent NES 
The exit of proteins from the nucleus is mainly regulated via the nuclear export 
receptors. The XPO1 protein, also known as exportin1 and CRM1, is the most 
versatile of all export receptors, being involved in the movement of many different 
classes of proteins (Nigg, 1997; Turner & Sullivan, 2008). To check this I used the 
specific CRM1 mediated nuclear export inhibitor LMB (leptomycin B); (Kudo et al., 
1998). ChikV capsid fused with GFP was transfected to HEK 293 cells and treated 
with leptomycin B. As shown in Fig. 8A and C, leptomycin B treatment leads to total 
nuclear accumulation of ChikV capsid-GFP (15 ± 6 times nuclear) whereas in un-
treated cells the protein was seen in both nucleus and cytoplasm (3 ± 1 times nuclear 
; Fig. 8B and C).  
 
  A  B  
 
Figure 8: ChikV capsid encodes a CRM1-dependent NES. (A). Leptomycin B treated, (B) Un-treated 
(C) Graphical representation, showing the nuclear cytoplasmic ratio of both leptomycin B treated and 
un-treated cells. 
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Table 3: Amino acid sequence analysis of various alpha virus isolates. 
 
3.3.2.4. Mapping of NES 
To identify a region of ChikV capsid that may contain a nuclear export signal, deletion 
mutants were constructed (Fig. 9). Deletion of 46 aa from C-terminal do not have any 
affect in the nuclear cytoplasmic translocation as it can be seen distributed throughout 
the cell (Fig. 10B and E). Removal of 118 aa from C-terminal localized the GFP fusion 
protein entirely to the nucleus (8 ± 3 times more nuclear; Fig. 10C and E). Regions of 
aa 148 to 152 that are rich in leucine residues were examined as potential NES sites. 
For this leucine’s at 149 and 152 were mutated to alanine, through overlap PCR. 
These amino acids were selected as it is conserved among most of the alphavirus 
isolates (table 3). Substitution of Leu to Ala in 149 and 152 positions (SDM) resulted 
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in decrease of cytoplasmic localization of protein (5 ± 1 times more nuclear Fig. 10D 
and E). 
 
 
Figure 9: Various GFP fusion constructs used in this study to map the nuclear export signal 
along with their observed localization. 
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Figure 10: Mapping of NES. ChikV cap-GFP Mutants were constructed through deletion or 
through site directed mutagenesis and the localisation of the protein was analyzed in HEK 293 
cells through confocal microscopy (A) ChikV capsid FL, (B) ChikV capsid ∆46 (C) ChikV capsid 
∆118 (D) Site directed mutant (DLAKL to DAAKA) (E) Ratio of nuclear to cytoplasmic 
concentration of GFP-fusion proteins, as a measure of nuclear import and export. 
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3.4. Discussion 
3.4.1. Alphavirus capsid protease: sequence requirements 
for activity 
The cleavage specificity of alphaviral capsid proteases has been characterized 
partially for SFV and Sindbis virus (Choi et al., 1996; Melancon & Garoff, 1987). The 
main determinants identified for site-specific cleavage is the conservation of W267 
(W261 in ChikV) (Skoging & Liljestrom, 1998) and an intact catalytic triad (Melancon 
& Garoff, 1987). An exchange of threonine for serine (S262T) failed to prevent this 
cleavage, and showed that serine is not important for its activity. Deletion of 46 aa 
from C-terminus inactivated the protease either by a change (deletion) in the 
cleavage site or due to a change in the tertiary structure. These results also showed 
that amino acids with in the C-terminus of the ChikV capsid are important for the 
activity of the capsid protease.  
 
It has been shown before in SFV capsid protease that W267 was essential for 
efficient viral growth (Skoging & Liljestrom, 1998). Mutating tryptophan 267 to 
alanine resulted in loss of cleavage activity and subsequent loss of viral replication. 
The dominant role of W267 for SFV replication leads us to analyze the role of other 
amino acids near tryptophan 261 in ChikV capsid. Mutation of other conserved or 
less conserved residues (Fig. 3A) close to tryptophan did not alter the activity of the 
ChikV protease (Fig. 3B). Our results further support the observation that the 
importance of tryptophan 267 in SFV is not related to a change in tertiary structure or 
improper folding but serves as sequence specific recognition signal for the 
autocatalytic triad (Skoging & Liljestrom, 1998). 
 
One mutant introduced by error-prone PCR resulted in complete loss of protease 
activity when isoleucine at 227 position was changed to lysine. Molecular modelling 
showed that the formation of a salt bridge between mutant K227 and D161 
potentially affects crucial functions of D161. D161 is one out of three conserved 
amino acid, forming the autocatalytic triad of the capsid protease. The probable salt 
bridge between K227 and D161 obviously disrupts the protease activity of the 
autocatalytic triad. In the native enzyme, D161 makes a low barrier hydrogen bond 
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(LBHB) with H139 (Frey et al., 1994). Due to this LBHB, H139 acts as general base 
and abstracts the proton from the S213 hydroxyl group. De-protonated S213 will act 
as a nucleophile and will form a tetrahedral transition state with carbonyl carbon of 
the substrate. The disruption of LBHB by N-methylation of histidine (Henderson, 
1971) or by mutation of D161 of the catalytic triad to asparagine has been shown to 
inactivate serine proteases (Craik et al., 1987). The potential salt bridge between 
D161 and mutant K227 may also disrupt the LBHB between D161 and H139 and 
may consequently make the enzyme inactive as the salt bridge can be very stable in 
the hydrophobic environment of the active site (Anderson et al., 1990). 
 
In conclusion, the analysis shows that I227 is located close to the catalytic triad of 
the ChikV capsid and a mutation of this residue leads to disruption of the protease 
activity. I am also showing that amino acids other than the catalytic triads are 
important for the activity of this serine protease of the ChikV capsid.  
3.4.2. Nuclear Import and export of ChikV capsid protein 
The Alphavirus genus of the Togaviridae family contains a number of important 
human and animal pathogens. In that New World alphavirus CP induces apoptosis 
through transcription inhibition that is mainly determined by the amino-terminal 
fragment of the protein or by the positively charged RNA-binding domain. In the case 
of Old World alphaviruses which includes ChikV, CP doesn’t induce transcriptional 
inhibition or apoptosis (Garmashova et al., 2007). Despite the localization of ChikV 
CP in the cytoplasm and nucleus, the molecular mechanism underlying this 
intracellular transport is unknown. Similarly unknown is the regulation of its import 
and export. Although the alphavirus capsid protein has multiple critical functions 
attributed to it, some of its function remains indefinable. Alphavirus CPs with a size 
of ~30 kDa are smaller than the molecular size required (> 40 kDa) for kar mediated 
nuclear transport (Paine et al., 1975). Still alphaviral CPs have been found to 
harbour NLS and the transport is energy dependent (Favre et al., 1994; Michel et al., 
1990). To investigate the mechanism that determines the nuclear-cytoplasmic 
distribution of ChikV CP, we evaluated if it is interacting with karyopherins, the 
protein which shuttles NLS containing proteins to the nucleus. Using pull-down 
assays we identified karα4 as a specific binding partner of the viral protein. It is likely 
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that karα4 physically binds to ChikV CP in the cytoplasm, and then interacts with 
importin-β1 at nuclear pores followed by a Ran-GTP-dependent translocation 
process through nuclear pores into the nucleus. 
  
Karα recognizes a variety of classical NLSs, like the very basic monopartite SV40 
large T antigen NLS (PKKKRKV), the more hydrophobic monopartite c-myc NLS 
(PAAKRVKLD), and the bipartite nucleoplasmin NLS (VKRPAATKKAGQAKKKKLD) 
(Collas & Alestrom, 1996; Nadler et al., 1997). Crystallographic analyses of karα 
bound to NLS peptides showed that the C-terminal minor binding site of karα 
comprising arm repeats 7 and 8 is able to bind NLS peptides. The crystal structure 
shows that the major NLS binding site of yeast karα molecule recognizes the 
classical monopartite NLS peptide of SV40 large T antigen and the larger 
downstream basic cluster of the classical bipartite NLS peptide. The minor NLS 
binding site has a supportive role in the binding of smaller basic cluster of the 
bipartite NLS (Conti & Kuriyan, 2000; Soisson et al., 1998). The c-myc NLS peptide 
(PAAKRVKLD) binds to major as well as minor binding sites of yeast karα (Conti & 
Kuriyan, 2000). Crystal structure of the C-terminal domain of influenza virus 
polymerase PB2 subunit also shows similar binding (Tarendeau et al., 2007). Mouse 
karα exhibits binding for the bipartite nucleoplasmin NLS as yeast karα, whereas 
SV40 large T antigen NLS peptide was shown to bind equally to the major and minor 
binding sites (Fontes et al., 2000). Karα has two NLS binding sites that directly 
interact with the NLS containing protein. Arm repeats 2–4 comprise the N-terminal 
NLS binding site and arm repeats 7–9 the C-terminal NLS binding site. The C-
terminal part of karα has been proposed to bind to various NLS. Through deletion 
analysis it has been shown that the NLS of Epstein-Barr virus (KRPRSPSS) and the 
matrix protein of HIV (KKKYKL) are bound through the C-terminal half of karα1 
(Fischer et al., 1997; Gallay et al., 1996). Through site-directed mutagenesis it has 
been shown that the C-terminal arm repeats 8 and 9 of karα5 form binding site for 
STAT1 homodimers and STAT1-STAT2 heterodimers (Melen et al., 2003). LEF-1 
NLS, a human transcription factor (NLSKKKKRKREK) is recognized by karα1 and 5 
and the binding was mapped to the C-terminus of karα1 (Herold et al., 1998). In case 
of Influenza A virus nucleoprotein (NP), which has a nonconventional NLS in its N-
terminal and is reported to be interacting with the C-terminal NLS binding site of 
karα5, comprising arm repeats 7–9. It also binds to karα3 via the C-terminal arm 
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repeats (Melen et al., 2003). Semliki Forest virus CP, is proposed to contain 2 NLS, 
66'KPKKKKTTKPKPKTQPKK'83 and 92'KKKDKQADKKKKKP’105 (Favre et al., 
1994) and with the putative 2 NLS sequences found in ChikV CP, 
60‘KPRRNRKNKKQKQK’73 and 84‘KKQPPKKKPAQKKKKP’99 it was tempting to 
look for the karα domain responsible for this binding. Through pull-down assay we 
found that the N-terminal NLS binding site of karα4 is sufficient for the ChikV CP 
NLS interaction. A deletion of the C-terminal NLS binding site from karα4 did not 
have any effect on molecular interaction. Further studies are needed to show how 
ChikV CP specifically utilizes karα3 and 4 instead of all available importins for 
nuclear import. 
 
The exit of proteins from the nucleus is mainly regulated via the nuclear export 
receptors. The CRM1 protein also known as XPO1, and exportin1, is the most 
versatile of all export receptors involved in the transport of many different classes of 
proteins (Nigg, 1997; Turner & Sullivan, 2008). CRM1 binding is often associated 
with leucine rich NES. The 10-15-residue LR-NESs was first identified in HIV-1 Rev 
and cyclic-AMP-dependent protein kinase inhibitor, and is recognized by the exportin 
CRM1. As the ChikV CP is present both in the nucleus and cytoplasm, we checked if 
it is CRM1 dependent. Leptomycin B has been shown to inhibit nuclear export of 
proteins due to alkylation of CRM1 (Kudo et al., 1999). Here treatment with 
leptomycin B on cells transfected with ChikV CP-GFP resulted in the complete 
inhibition of nuclear export. 
 
I further tested some deletion mutants fused to GFP to fine map the NES in the 
ChikV capsid. Removal of 46 aa from the C-terminus had no effect while removal of 
118 aa made the protein exclusively nuclear. Analysis of the sequence revealed 
repeats of leucine rich regions between 148th and 162nd residues of ChikV capsid. 
Leucines in the 149th and the 152nd position were found to be highly conserved in 
different ChikV isolates and most of the alphaviruses (table 3). Substitution of these 
with alanine made the protein mostly nuclear and confirmed the CRM1 dependent 
NES. Thus the NES was mapped between aa 149 and 152 of the ChikV capsid. 
Even though region between aa 149 and 152 was found important for the CRM1 
dependent nuclear export, the nuclear cytoplasmic ratio was only 5 ± 1 times more 
nuclear (Fig. 10D and E) compared to 15 ± 6 times nuclear ( Fig. 8A and C ) after the 
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leptomycin B treatment. This may be due to the fact that Chik V capsid may be 
encoding another CRM1 dependent NES other than that mapped between 149 and 
152 positions. It is also possible that some other factors may be modulating the 
nuclear export of proteins. It may include phosphorylation as in the case of proteins 
like p53 were phosphorylation of ser15/20 in p53 in response to DNA damage leads 
to NES1 masking. Another mechanism consists in tetramerization of protein p53 
within the nucleus in response to the DNA damage, NES2 is masked in tetrameric 
p53. Dissociation of this tetramer is required for the export of the protein from the 
nucleus (Stommel et al., 1999). In case of androgen receptor, masking of NES/NLS 
as was shown in which NES is in the ligand-binding domain. In the presence of the 
ligand (androgen), NES is masked and Crm1 cannot recognize it. The receptor is 
translocated only after the dissociation of androgen (Saporita et al., 2003). Here I am 
assuming that other regions may be important for the proper stability of the protein to 
be cytoplasmic or it is possible that the phosphorylation sites in it may be important 
for the modulation through the recognition by exportin 1 and thus the export of ChikV 
capsid. 
 
To conclude we are showing that ChikV capsid is recognized by karyopherins and its 
export is mediated by CRM1 dependent nuclear export signal. 
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4. Summary 
The main functions of viral capsids are to protect, transport and deliver the viral 
genome. I investigated some of these aspects of two positive stranded RNA viruses, 
Hepatitis E virus (HEV) and Chikungunya virus (ChikV), an alphavirus. I was able to 
detect HEV in swine sera collected from Western and Northern Germany. This 
shows the vulnerability of German population to HEV and the necessity for stringent 
screening of swine farms in Germany for HEV. I also expressed HEV capsid in 
various expression systems. The use of HEV capsid as a vaccine candidate is 
discussed using an adenovirus based expression system. One of the main problems 
that have hindered the HEV research is the lack of a good infectious system. Using 
clone pJE03-1760 I was able to establish an infectious system which was well 
propagating in the cells. This system was further used to analyse the role of 
cholesterol in virus egress. I found that simvastatin treatment hindered HEV 
egress.However simvastatin had no significant effect on HEV genome replication. 
Our data suggest simvastatin as a promising drug candidate for treating HEV. 
 
Although the alphavirus capsid protein has multiple critical functions ascribed to it, 
some of its functions remain elusive. Alphaviral replication depends on the efficient 
and precise cleavage after tryptophan 261 executed by the capsid protease. I looked 
at the requirement of various amino acid sequences for the efficient cleavage of this 
protease using ChikV capsid. My analysis shows that amino acids other than the 
catalytic triads are important for the activity of the serine protease of the ChikV 
capsid. Despite the localization of ChikV capsid in both, cytoplasm and nucleus, its 
molecular mechanism is still unknown. Similarly unknown is the regulation of its 
import and export. Using various methods I was able to show that ChikV capsid is 
recognized by karyopherins and its export is mediated by a CRM1 dependent 
nuclear export signal. 
 
These findings can be used for approach towards antiviral drugs or vaccines that 
target viral capsids. 
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